



**UNIVERSITI PUTRA MALAYSIA**

***PHYSICOCHEMICAL CHARACTERIZATION AND IN VITRO  
ANTI-CANCER EFFECTS OF IRON-MANGANESE AND  
IRON-DOPED SULFATED ZIRCONIA NANOPARTICLES  
IN CANCER CELL LINES***

**MOHAMED QASIM KHLAIF**

**IB 2016 4**



**PHYSICOCHEMICAL CHARACTERIZATION AND *IN VITRO*  
ANTI-CANCER EFFECTS OF IRON-MANGANESE AND  
IRON-DOPED SULFATED ZIRCONIA NANOPARTICLES  
IN CANCER CELL LINES**

By

**MOHAMED QASIM KHLAIF**



**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia, in  
Fulfilment of the Requirements for the degree of Master of Science**

**April 2016**



## **COPYRIGHT**


All material contained within the thesis, including without limitation text, logos, icons, photographs and all other artwork, is copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of Universiti Putra Malaysia.

Copyright © Universiti Putra Malaysia



## **DEDICATION**

I wish to dedicate this thesis to my mother (Samerah Obaid) and father (Qasim K. Al-Fahdawi) for their love and giving me the genes for research. They have always believed in me and have always encouraged me not only during this master period but throughout life.



Abstract of the thesis presented to the Senate of Universiti Putra Malaysia in fulfilment  
of the requirement for the degree of Master of Science

**PHYSICOCHEMICAL CHARACTERIZATION AND *IN VITRO*  
ANTI-CANCER EFFECTS OF IRON-MANGANESE AND  
IRON-DOPED SULFATED ZIRCONIA NANOPARTICLES  
IN CANCER CELL LINES**

By

**MOHAMED QASIM, KHLAIF**

**April 2016**

**Chairman : Professor Rasedee Abdullah, PhD**  
**Faculty : Institute of Bioscience**

Crystal nanoparticle is a new system with potential as a therapeutic agent in the treatment of diseases. The objectives of this study are to synthesize, characterize and determine the anticancer cell effects of iron-manganese and iron-doped sulfated zirconia nanoparticles. In this study the iron-manganese- and iron-doped sulfated zirconia nanoparticles were prepared by hydrothermal impregnation method followed by calcination. The characterization of both nanoparticles were carried out using X-ray diffraction (XRD), thermal gravimetric analysis (TGA), fourier transform infrared spectroscopy (FT-IR), Brunner-Emmett-Teller (BET) surface area measurements, X-ray fluorescence (XRF), X-ray photoelectron spectroscopy, zeta potential (ZSP) measurement, and transmission electron microscopy (TEM). The cytotoxicity of the nanoparticles was determined via the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay on human breast adenocarcinoma (MDA-MB-231), colorectal adenocarcinoma (HT29), and hepatocellular carcinoma (HepG2) cell lines, and two normal human cell lines, the Chang liver and human umbilical vein endothelial cells (HUVEC) cell lines. The results showed that the iron-manganese- and iron-doped sulfated zirconia nanoparticles were of average size 12.7 and 32.0 nm, respectively and zeta potential of 15.0 and 0.206 mV, respectively. These nanoparticles tend to aggregate in solution. The iron-manganese- and iron-doped sulfated zirconia nanoparticles are highly toxic to the MDA-MB-231 and HepG2 cells, respectively, showing dramatic morphological changes suggesting loss of cell viability. The nanoparticles are comparatively less toxic to the HT29 cells compared to the other cancer cell lines. The study suggests that the anticancer effects of iron-manganese- and iron-doped sulfated zirconia nanoparticles implicate caspase-3, 8 and -9 in their anticancer cells activities. The findings from the study highlight the potential of iron-manganese- and iron-doped sulfated zirconia nanoparticles as therapeutic agents in the treatment of cancers, while showing lesser effect on normal cells.

**Keywords:** iron-manganese-doped sulfated zirconia nanoparticles, iron-doped sulfated zirconia nanoparticles, physiochemical characterization, cytotoxicity, HepG2, MDA-MB-231, HT29, HUVEC, Chang cell.



Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Master Sains

**PENCIRIAN FISIKOKIMIA DAN KESITOKSIKAN NANOZARAH  
ZIRKONIA BERSULFAT TERDOP FERUM-MANGAN DAN FERUM**

Oleh

**MOHAMED QASIM. KHLAIF**

**April 2016**

**Pengerusi : Profesor Rasedee Abdullah, PhD**  
**Fakulti : Institut Biosains**

Nanozarah hablur merupakan suatu sistem baharu yang berpotensi sebagai agen terapi dalam rawatan penyakit. Objektif kajian ini ialah untuk mensintesis, menciri, dan menentukan kesan antisel kanser nanozarah zirkonia bersulfat terdop ferum-mangan dan ferum. Dalam kajian ini nanozarah zirkonia bersulfat terdop ferum-mangan dan ferum disediakan melalui kaedah pengisian hidrotermal diikuti dengan pengkalsinan. Pencirian kedua-dua nanozarah dijalankan menggunakan pembelauan X-sinar (XRD), analisis gravimetric terma, spektroskopi inframerah transformasi Fourier (FT-IR), pengukuran kawasan permukaan Brunner-Emmett-Teller (BET), pendarfluoran X-sinar (XRF), spektroskopi fotoelektron X-sinar, pengukuran keupayaan zeta (ZSP), mikroskopi electron pancaran (TEM). Kesitoksikan nanozarah ditentukan melalui assai (4,5-dimetiltiazol-2-yl)-2,5-difeniltetrazolium bromide (MTT) terhadap titisan sel adenokarsinoma payudara (MDA-MB-231), adenokarsinoma kolorektum (HT29), karsinoma hepatosel (HepG2) manusia, dan dua titisan sel normal manusia iaitu sel hati (Chang) dan sel endothelium vena umbilikus (HUVEC). Hasil kajian menunjukkan nanozarah zirkonia bersulfat terdop ferum-mangan dan ferum masing-masing berpurata saiz 12.7 dan 32.0 nm, dan keupayaan zeta masing-masing 15.0 dan 0.206 mV. Nanozarah ini cenderung untuk mengagregat dalam larutan. Nanozarah zirkonia bersulfat terdop ferum-mangan dan ferum adalah paling toksik masing-masing kepada sel MDA-MB-231 dan HepG2, menunjukkan perubahan morfologi ketara yang menyaran hilangnya kebolehdijalan sel. Nanozarah ini kurang toksik terhadap sel HT29 berbanding titisan sel kanser lain. Kajian ini menyarangkan yang kesan antikanser nanozarah zirkonia bersulfat terdop ferum-mangan dan ferum melibatkan kaspase-3, -8, dan -9 dalam aktiviti antisel kansernya. Hasil kajian ini mengutarakan potensi nanozarah zirkonia bersulfat terdop ferum-mangan dan ferum sebagai agen terapi dalam rawatan kanser, sambil tidak menunjukkan banyak kesan terhadap sel normal.

**Katakunci:** nanozarah zirkonia bersulfat terdop ferum-mangan, nanozarah zirkonia bersulfat terdop ferum, pencirian fisiokimia, kesitoksikan, HepG2, MDA-MB-231, HT29, sel Chang.

## ACKNOWLEDGEMENTS

In the Name of Allah, Most Gracious, Most Merciful, all praise and thanks are due to Allah, and peace and blessings be upon His Messenger. I would like to express the most sincere appreciation to those who made this work possible: Advisory members, Friends and Family.

I would like to thank **Prof. Dr Rasedee Abdullah** for providing me the opportunity to complete my MSc studies under his valuable guidance, for the many useful advice and discussions, for his constant encouragement and guidance, and for co-authoring and reviewing some of my publications, where his practical experience and technical knowledge made this research and those publications more interesting and relevant. In addition, special thanks extend to the supervisory committee member; **Prof. Dr. Yun Hin Taufiq-Yap** and **Prof. Dr. Rozita Rosli**. I am grateful for their willingness to serve on my supervisory committee, constant encouragement, helpful advice and many fruitful discussions.

Thanks and acknowledgements are meaningless if not extended to my dearest friend **Mothanna Sadiq Obaid Al-Qubaisi** who deserves my deepest appreciation. I am grateful for the countless sacrifices he made to ensure that I could pursue my dreams and for always being there for me. Real and deepest thanks to him (May ALLAH bless and protect him and may he live long and healthy life). All praise and thanks words said to him will not be enough.

Thank you.

I certify that a Thesis Examination Committee has met on 27 April 2016 to conduct the final examination of Mohammed Qasim Khlaif on his thesis entitled "Physicochemical Characterization and *In Vitro* Anti-Cancer Effects of Iron-Manganese and Iron-Doped Sulfated Zirconia Nanoparticles in Cancer Cell Lines" in accordance with the Universities and University Colleges Act 1971 and the Constitution of the Universiti Putra Malaysia [P.U.(A) 106] 15 March 1998. The Committee recommends that the student be awarded the Master of Science.

Members of the Thesis Examination Committee were as follows:

**Rosnina Bt Haji Yusoff, PhD**  
Associate Professor  
Faculty of Veterinary Medicine  
Universiti Putra Malaysia  
(Chairman)

**Gayathri Thevi Selvarajah, PhD**  
Senior Lecturer  
Faculty of Veterinary Medicine  
Universiti Putra Malaysia  
(Internal Examiner)

**Abdelwahid Saeed Ali Babiker, PhD**  
Professor  
King Khalid University  
Saudi Arabia  
(External Examiner)



---

**ZULKARNAIN ZAINAL, PhD**  
Professor and Deputy Dean  
School of Graduate Studies  
Universiti Putra Malaysia

Date: 28 June 2016

This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfillment of the requirement for the degree of Master of Science. The members of the Supervisory Committee were as follows:

**Rasedee Abdullah, PhD**

Professor

Faculty of Veterinary Medicine  
Universiti Putra Malaysia  
(Chairman)

**Yun Hin Taufiq-Yap, PhD**

Professor

Faculty of Science  
Universiti Putra Malaysia  
(Member)

**Rozita Rosli, PhD**

Professor

Faculty of Medicine and Health Science  
Universiti Putra Malaysia  
(Member)

---

**BUJANG KIM HUAT, PhD**

Professor and Dean

School of Graduate Studies  
Universiti Putra Malaysia

Date:

### **Declaration by graduate student**

I hereby confirm that:

- this thesis is my original work;
- quotations, illustrations and citations have been duly referenced;
- this thesis has not been submitted previously or concurrently for any other degree at any other institutions;
- intellectual property from the thesis and copyright of thesis are fully-owned by Universiti Putra Malaysia, as according to the Universiti Putra Malaysia (Research) Rules 2012;
- written permission must be obtained from supervisor and the office of Deputy Vice-Chancellor (Research and Innovation) before thesis is published (in the form of written, printed or in electronic form) including books, journals, modules, proceedings, popular writings, seminar papers, manuscripts, posters, reports, lecture notes, learning modules or any other materials as stated in the Universiti Putra Malaysia (Research) Rules 2012;
- there is no plagiarism or data falsification/fabrication in the thesis, and scholarly integrity is upheld as according to the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) and the Universiti Putra Malaysia (Research) Rules 2012. The thesis has undergone plagiarism detection software.

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Name and Matric No.: Mohammed Qasim Khlaf, GS 40965

### Declaration by Members of Supervisory Committee

This is to confirm that:

- the research conducted and the writing of this thesis was under our supervision;
- supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) are adhered to.

Signature:   
Name of Chairman of Supervisory Committee: **PROF DR RASEDEE ABDULLAH**  
**Dept. of Veterinary Laboratory Diagnosis**  
**FACULTY OF VETERINARY MEDICINE**  
**Universiti Putra Malaysia**

Signature: \_\_\_\_\_

Name of Member of Supervisory Committee: \_\_\_\_\_

Signature:   
Name of Member of Supervisory Committee: **PROF. DR. ROZITA ROSLI**  
**Ketua Laboratori Penyelidikan Kanser UPM-MAKNA**  
**Institut Biosains**  
**Universiti Putra Malaysia**  
**43400 UPM, Serdang**  
**Selangor.**

Signature:   
Name of Member of Supervisory Committee: **PROFESSOR DR. TAUFIQ YAP YUN**  
**Deputy Director**  
**Supervisory Grant Division (Public Grant)**  
**Research Management Centre (RMC)**  
**Universiti Putra Malaysia**  
**Serdang, Selangor Darul Ehsan**

## TABLE OF CONTENTS

	Page
<b>ABSTRACT</b>	i
<b>ABSTRAK</b>	iii
<b>ACKNOWLEDGEMENTS</b>	iv
<b>APPROVAL</b>	v
<b>DECLARATION</b>	vii
<b>LIST OF TABLES</b>	xii
<b>LIST OF FIGURES</b>	xiii
<b>LIST OF ABBREVIATIONS</b>	xv
<b>CHAPTER</b>	
<b>1      INTRODUCTION</b>	1
1.1    Introduction	1
1.2    Objectives	2
1.2.1    General objective	2
1.2.2    Specific objectives	2
<b>2      LITERATURE REVIEW</b>	3
2.1    Cancer	3
2.1.1    Background	3
2.1.2    Liver cancer	4
2.1.3    Breast cancer	5
2.1.4    Colon cancer	6
2.1.5    Chemotherapy	8
2.2    Nanotechnology	8
2.3    Techniques used in nanotechnology	9
2.3.1    X-ray photoelectron spectroscopy	9
2.3.2    X-ray fluorescence spectrometer	9
2.3.3    X-ray diffraction	9
2.3.4    Fourier Transform Infrared	10
2.3.5    Brunauer, Emmett and Teller analysis	10
2.3.6    Barrett-Joyner-Halenda analysis	10
2.3.7    Thermogravimetric analysis	10
2.3.8    Transmission electron microscopy	11
2.3.9    Zetasizer	11
2.4    Transition Metals	11
2.4.1    Anticancer effects	12
2.5 <i>In Vitro</i> Cytotoxicity	13
2.5.1    MTT assay	13
2.5.2    Caspases	13

<b>3</b>	<b>MATERIALS AND METHODS</b>	15
3.1	Chemicals and reagents	15
3.2	Preparation of nanoparticles	15
3.2.1	Preparation iron-manganese-doped sulphated zirconia nanoparticle	15
3.2.2	Preparation of iron-doped sulfated zirconia nanoparticle	15
3.3	Physicochemical Properties of nanoparticles	16
3.3.1	X-ray photoelectron spectrum	16
3.3.2	Thermogravimetric analysis	16
3.3.3	Fourier transform infrared	16
3.3.4	Brunauer, Emmett and Teller analysis	16
3.3.5	X-ray Diffraction	16
3.3.6	Transmission electron microscopy	17
3.3.7	Zeta potential	17
3.4	Cell Culture	17
3.5	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Assay	17
3.6	Microscopic examination of cell morphology	18
3.7	Caspase activities	18
3.8	Statistical analysis	18
<b>4</b>	<b>CYTOTOXICITY AND PHYSICOCHEMICAL CHARACTERIZATION OF IRON–MANGANESE DOPED SULFATED ZIRCONIA NANOPARTICLES</b>	19
4.1	Introduction	19
4.2	Materials and Methods	20
4.3	Results and Discussion	20
4.3.1	Characterization	20
4.3.2	Cellular Sensitivity of Cancer and Normal Cells to Iron manganese-doped Sulfated Zirconia Nanoparticles	27
4.3.3	Morphology of treated cell lines	31
4.4	Conclusions	33
<b>5</b>	<b>CYTOTOXICITY AND PHYSICOCHEMICAL CHARACTERIZATION OF IRON-DOPED SULFATED ZIRCONIA NANOPARTICLES</b>	34
5.1	Introduction	34
5.2	Materials and Methods	35
5.3	Results and Discussion	35
5.3.1	Material Characterization	35
5.3.2	Cellular Sensitivity of Cancer and Normal Cells to Iron doped Sulfated Zirconia Nanoparticles	41
5.3.3	Caspases activities	45
5.3.3.1	Caspase-3	45
5.3.3.2	Caspase-8	46
5.3.3.3	Caspase-9	47
5.3.4	Morphology	48
5.4	Conclusion	50

<b>6 GENERAL DISCUSSION</b>	51
<b>7 CONCLUSION</b>	53
<b>REFERENCES</b>	54
<b>BIODATA OF STUDENT</b>	85
<b>LIST OF PUBLICATIONS</b>	86



## LIST OF TABLES

Table		Page
4.1	IC <sub>50</sub> values of iron–manganese doped sulfated zirconia nanoparticle and drugs on cell lines based on MTT assay following exposure for 72 hours.	31
5.1	IC <sub>50</sub> values of iron-doped sulfated zirconia nanoparticles and drugs on cancer cells at 72 hours	42

## LIST OF FIGURES

<b>Figure</b>		<b>Page</b>
2.1	Periodic table.	12
2.2	The cell death machinery	14
4.1	X-ray photoelectron spectra of iron (+3)-manganese promoted sulfated zirconia.	22
4.2	TGA-DTG thermograph of iron (+3)-manganese promoted sulfated zirconia sample.	23
4.3	Fourier transforms infrared spectrum of iron (+3)-manganese promoted sulfated zirconia sample.	24
4.4	XRD pattern of $\text{Fe}^{3+}\text{-Mn}^{4+}\text{-SO}_4/\text{ZrO}_2$ sample calcined at 650 °C for 5h.	25
4.5	Transmission electron microscopic image of $\text{Fe}^{3+}\text{-Mn}^{4+}\text{-SO}_4/\text{ZrO}_2$ sample calcined at 650 °C for 5h.	26
4.6	Surface charge properties of $\text{Fe}^{3+}\text{-Mn}^{4+}\text{-SO}_4/\text{ZrO}_2$ nanoparticle.	27
4.7	Effect of iron–manganese doped sulfated zirconia nanoparticle and chemotherapeutic on the viability of cells determined by through mitochondrial activity using the 4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay.	29,30
4.8	Effect of treatment with iron–manganese doped sulfated zirconia nanoparticle at their respective 72-hour IC50 concentrations on cells morphology.	32,33
5.1	XRD pattern of $\text{Fe}^{3+}\text{-SO}_4/\text{ZrO}_2$ sample calcined at 700 °C for 5h.	36
5.2	X-ray photoelectron profiles of iron-doped sulfated zirconia nanoparticles.	37
5.3	TGA-DTG thermogravimetry profile of the of iron-doped sulfated zirconia nanoparticle sample.	38
5.4	FT-IR spectrum of iron-doped sulfated zirconia nanoparticles.	39
5.5	Surface charge properties of iron-doped sulfated zirconia nanoparticles.	40
5.6	Transmission electron microscopic image of iron-doped sulfated zirconia nanoparticles calcined at 700 °C for 5h.	41

5.7	Effect of iron-doped sulfated zirconia nanoparticles and drugs on the viability of cells determined by the (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay.	43,44
5.8	Effect of treatment with NP1 and NP2 at 24 hour IC <sub>50</sub> concentrations on the caspase-3 activity in cell lines.	46
5.9	Effect of treatment with NP1 and NP2 at 24 hour IC <sub>50</sub> concentrations on the caspases-8 activity in cell lines.	47
5.10	Effect of treatment with NP1 and NP2 at 24 hour IC <sub>50</sub> concentrations on the caspases-9 activity in cell lines.	48
5.11	The effect of iron-doped sulfated zirconia nanoparticle treatment at 72-hour IC <sub>50</sub> concentrations on cells	49,50

## LIST OF ABBREVIATIONS

ATCC	The American Type Culture Collection
CO <sub>2</sub>	Carbon dioxide
DMEM	Dulbecco's modified Eagle's medium
DMSO	Dimethyl sulphoxide
DTT	Dithiothreitol
dUTP	2'-deoxyuridine 5'-triphosphate
EDTA	Ethylenediaminetetraacetic acid
ELISA	Enzyme-linked Immunosorbent Assay
EtOH	Ethanol
FBS	Fetal bovine serum
XRD	X-ray diffraction
XRF	X-ray fluorescence
XPS	X-ray photoelectron spectroscopy
TGA	Thermogravimetric analysis
FTIR	Fourier transform infrared
TEM	Transmission electron microscopy
HCl	Hydrochloric acid
IC <sub>50</sub>	Inhibition concentration at 50 percent
KCl	Potassium Chloride
KH <sub>2</sub> PO <sub>4</sub>	Potassium dihydrogen phosphate
LDH	Lactate Dehydrogenase
BET	Brunauer, Emmett and Teller analysis
MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NaCl	Sodium Chloride
NADH	Nicotinamide adenine dinucleotide
NaHPO <sub>4</sub>	Disodium hydrogen phosphate anhydrous
NaOH	Sodium hydroxide
PBS	Phosphate buffer saline

HepG2	Human hepatocellular carcinoma cell line
HT29	Human colorectal adenocarcinoma cell line
MDA-MB231	Human breast adenocarcinoma cell line
HUVEC	Human umbilical vein endothelial cell line
Chang	Human normal hepatocyte cell line



## CHAPTER 1

### INTRODUCTION

#### 1.1 Introduction

Cancer is one of the common reason of death in the developed countries and has exceeded the cardiovascular diseases as the main death cause for people under 80 years old (Siegel et al., 2014). Cancers are induced by changes at molecular level leading to uncontrolled growth, and probably metastasized to other parts of the body (Leemans et al., 2011). There is continuous developing and growth in strategies used for the development of anticancer drugs (Seddon & Workman 2014). Using nanotechnology to treat cancer is one of these strategies. In fact, nanotechnology is one of the most current research area in cancer treatments (Jain et al., 2014). The mode of cancer treatments are gradually changing from surgical removal, chemotherapies, radiotherapy, immunotherapy (Lewis et al., 2014; Feldman et al., 2015) to the use of innovative means such as nanoparticle drug delivery systems (Liao et al., 2014) that facilitate controlled release of drugs (Jain et al., 2014) at nano-scale range (Brannon-Peppas & Blanchette 2012; Alimohammadi & Joo 2014). Thus, parallel to the explosion of knowledge on the biomedical and biochemical understanding of cancer development, nanotechnology is now becoming a weapon in the war against cancer (Jain 2014; Tan et al., 2014). It is well-known that the metallic elements have unique biological properties (Wang et al., 2012; Liao et al., 2014). This is attributed to their ability to easily lose electrons and produce soluble cations in biological fluids, while functioning as charged vehicles in the body and cellular mechanisms, such as sodium-potassium pump. When in combination with biological molecules e.g. nucleic acids and proteins, metallic elements function to sustain life through the supply essential molecules such as oxygen (Turner et al., 2008; Greeley et al., 2009; van Rijt & Sadler 2009; Nordberg et al., 2014).

Positively charged metal ions can facilitate catalysis (Xu et al., 2014) through the control of flow of electrons in enzyme or its substrate (Wang et al., 2011; Fu et al., 2014; Pernicova & Korbonits 2014). Many of these oxidation-reduction reactions are provided by multivalent metal ions (Moodley 2014; Morant-Miñana 2014; Nkuna 2014). Since ancient times, transition metals have been used in medicine (Orvig & Abrams 1999; Nordqvist & Herva 2013; Owunari et al., 2015). Ancient Egyptian chemists used copper to disinfect the water (Grass et al., 2011; Murari et al., 2015) while the gold was incorporated into many traditional Chinese medicine (Owunari et al., 2015; Smardzewski 2015; Xin 2015). In spite of that, the study of anticancer potency of transition metals, such as cisplatin, began to pick up about 40 years ago (Dasari & Tchounwou 2014; Schefter et al., 2014). It is generally believed that the cisplatin targets both nucleic acids, DNA (Olaussen et al., 2006) and RNA (Xiang et al., 2014) along with mitochondria (Yang et al., 2006) and other functional proteins rich in sulfur groups (Dasari & Tchounwou 2014). Cisplatin can penetrate tumor cells, and this process is either via passive (Ciarimboli 2014) or active (Burger et al., 2011). Transition metals-containing nanoparticles have fewer side-effects and cheaper to produce than the available chemotherapeutic compounds (Muhammad & Guo 2014). In this study, two zirconium-based nanoparticles, ferric-doped sulfated zirconia and iron-

manganese doped-sulfated zirconia nanoparticles were developed as potential anticancer compounds. The anticancer properties of these nanoparticles were tested on three human cancer cell lines, the colorectal adenocarcinoma (HT29), hepatocellular carcinoma (HepG2), and breast adenocarcinoma (MDA-MB-231) cells. Application of these nanoparticles as chemotherapeutic agents are governed by the following concerns: suitability of hydrothermal impregnation method in the synthesis of zirconia-containing nanoparticles, cytotoxicity towards cancer cells, selectivity of the nanoparticles for cancer cell lines, and the death pathway by which the nanoparticles exert their actions. In this study two zirconium-based nanoparticles, ferric doped sulfated zirconia and iron–manganese doped sulfated zirconia nanoparticles were prepared, characterized and their *in vitro* cytotoxicity on cancer cell lines evaluated.

## 1.2 Objectives

### 1.2.1 General objective:

The present study was undertaken to prepare and characterize the physicochemical properties and anticancer cell effects of two nanoparticles containing zirconium.

### 1.2.2 Specific objectives:

**The specific objectives of the study are to:**

1. Synthesize and characterize the physical properties of iron–manganese- and iron-doped sulfated zirconia nanoparticles.
2. Assess the cytotoxicity of iron–manganese- and iron-doped sulfated zirconia nanoparticles on MDA-MB-231, HT29, and HepG2 cell lines.
3. Determine the activity of caspases -3, -8 and -9 in cancer cells treated with iron–manganese- and iron-doped sulfated zirconia nanoparticles.

## REFERENCES

- Abedin, M., D. Wang, M. McDonnell, U. Lehmann & A. Kelekar 2007. Autophagy delays apoptotic death in breast cancer cells following DNA damage. *Cell Death & Differentiation* **14**(3): 500-510.
- Acton, Q. A. 2012. Colon Cancer: New Insights for the Healthcare Professional Ed.
- Adami, H. O., A. W. Hsing, J. K. McLaughlin, D. Trichopoulos, D. Hacker, A. Ekbom & I. Persson 1992. Alcoholism and liver cirrhosis in the etiology of primary liver cancer. *International Journal of Cancer* **51**(6): 898-902.
- Adrain, C., E. A. Slee, M. T. Harte & S. J. Martin 1999. Regulation of apoptotic protease activating factor-1 oligomerization and apoptosis by the WD-40 repeat region. *Journal of Biological Chemistry* **274**(30): 20855-20860.
- Ågesen, T. H., A. Sveen, M. A. Merok, G. E. Lind, A. Nesbakken, R. I. Skotheim & R. A. Lothe 2012. ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. *Gut* **61**(11): 1560-1567.
- Aghapoor, K., L. Ebadi-Nia, F. Mohsenzadeh, M. Mohebi Morad, Y. Balavar & H. R. Darabi 2012. Silica-supported bismuth (III) chloride as a new recyclable heterogeneous catalyst for the Paal-Knorr pyrrole synthesis. *Journal of Organometallic Chemistry* **708**: 25-30.
- Ahamed, M., M. S. Alsalhi & M. Siddiqui 2010. Silver nanoparticle applications and human health. *Clinica chimica acta* **411**(23): 1841-1848.
- Ajayan, P. M. & O. Z. Zhou. 2001. Applications of carbon nanotubes. Dlm. (pnyt.). Ed. *Carbon nanotubes* pp. 391-425. Springer.
- Al-Fahdawi, M., A. Rasedee, F. H. Alhassan, M. S. Al-Qubaisi, R. Rosli, M. E. El Zowalaty, M. Sh-eldin, T. J. Webster & Y. H. Taufiq-Yap 2015. Cytotoxicity and physicochemical characterization of iron – manganese doped sulfated zirconia nanoparticles. *International Journal of Nanomedicine* Accepted.
- Al-Qubaisi, M., R. Rozita, S.-K. Yeap, A.-R. Omar, A.-M. Ali & N. B. Alitheen 2011. Selective cytotoxicity of goniothalamin against hepatoblastoma HepG2 cells. *Molecules* **16**(4): 2944-2959.
- Al-Qubaisi, M. S., A. Rasedee, M. H. Flaifel, S. H. Ahmad, S. Hussein-Al-Ali, M. Z. Hussein, E. E. Eid, Z. Zainal, M. Saeed & M. Ilowefah 2013. Cytotoxicity of nickel zinc ferrite nanoparticles on cancer cells of epithelial origin. *International Journal of Nanomedicine* **8**: 2497.
- Alemán, G., V. Ortíz, E. Langley, A. R. Tovar & N. Torres 2005. Regulation by glucagon of the rat histidase gene promoter in cultured rat hepatocytes and human hepatoblastoma cells. *American Journal of Physiology-Endocrinology and Metabolism* **289**(1): E172-E179.

- Alhassan, F. H., U. Rashid, M. S. Al-Qubaisi, A. Rasedee & Y. H. Taufiq-Yap 2014. The effect of sulfate contents on the surface properties of iron–manganese doped sulfated zirconia catalysts. *Powder Technology* **253**: 809-813.
- Alimohammadi, Y. H. & S. W. Joo 2014. PLGA-based nanoparticles as cancer drug delivery systems. *Asian Pac J Cancer Prev* **15**: 517-535.
- Aloia, T., M. Sebagh, M. Plasse, V. Karam, F. Lévi, S. Giacchetti, D. Azoulay, H. Bismuth, D. Castaing & R. Adam 2006. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. *Journal of Clinical Oncology* **24**(31): 4983-4990.
- Alt, V., T. Bechert, P. Steinrücke, M. Wagener, P. Seidel, E. Dingeldein, E. Domann & R. Schnettler 2004. An *in vitro* assessment of the antibacterial properties and cytotoxicity of nanoparticulate silver bone cement. *Biomaterials* **25**(18): 4383-4391.
- Amara, D., I. Felner, I. Nowik & S. Margel 2009. Synthesis and characterization of Fe and Fe<sub>3</sub>O<sub>4</sub> nanoparticles by thermal decomposition of triiron dodecacarbonyl. *Colloids and Surfaces A: Physicochemical and Engineering Aspects* **339**(1): 106-110.
- André, T., C. Boni, M. Navarro, J. Tabernero, T. Hickish, C. Topham, A. Bonetti, P. Clingen, J. Bridgewater & F. Rivera 2009. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. *Journal of Clinical Oncology* **27**(19): 3109-3116.
- Ang, K. K., J. Harris, R. Wheeler, R. Weber, D. I. Rosenthal, P. F. Nguyen-Tân, W. H. Westra, C. H. Chung, R. C. Jordan & C. Lu 2010. Human papillomavirus and survival of patients with oropharyngeal cancer. *New England Journal of Medicine* **363**(1): 24-35.
- Arndt, V., H. Merx, C. Stegmaier, H. Ziegler & H. Brenner 2004. Quality of life in patients with colorectal cancer 1 year after diagnosis compared with the general population: a population-based study. *Journal of Clinical Oncology* **22**(23): 4829-4836.
- Asharani, P., M. P. Hande & S. Valiyaveettil 2009. Anti-proliferative activity of silver nanoparticles. *BMC cell biology* **10**(1): 1.
- AshaRani, P., G. Low Kah Mun, M. P. Hande & S. Valiyaveettil 2008. Cytotoxicity and genotoxicity of silver nanoparticles in human cells. *ACS nano* **3**(2): 279-290.
- Ashkenazi, A. 2002. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. *Nature Reviews Cancer* **2**(6): 420-430.

- Bar-Shalom, R., N. Yefremov, L. Guralnik, D. Gaitini, A. Frenkel, A. Kuten, H. Altman, Z. Keidar & O. Israel 2003. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. *Journal of nuclear medicine* **44**(8): 1200-1209.
- Barty, A., R. A. Kirian, F. R. Maia, M. Hantke, C. H. Yoon, T. A. White & H. Chapman 2014. Cheetah: software for high-throughput reduction and analysis of serial femtosecond X-ray diffraction data. *Journal of applied crystallography* **47**(3): 1118-1131.
- Behera, D. & B. Acharya 2008. Nano-star formation in Al-doped ZnO thin film deposited by dip-dry method and its characterization using atomic force microscopy, electron probe microscopy, photoluminescence and laser Raman spectroscopy. *Journal of Luminescence* **128**(10): 1577-1586.
- Berger, A. C., E. R. Sigurdson, T. LeVoyer, A. Hanlon, R. J. Mayer, J. S. Macdonald, P. J. Catalano & D. G. Haller 2005. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. *Journal of Clinical Oncology* **23**(34): 8706-8712.
- Berry, D. A., K. A. Cronin, S. K. Plevritis, D. G. Fryback, L. Clarke, M. Zelen, J. S. Mandelblatt, A. Y. Yakovlev, J. D. F. Habbema & E. J. Feuer 2005. Effect of screening and adjuvant therapy on mortality from breast cancer. *New England Journal of Medicine* **353**(17): 1784-1792.
- Bertrand, N., J. Wu, X. Xu, N. Kamaly & O. C. Farokhzad 2014. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. *Advanced drug delivery reviews* **66**: 2-25.
- Bi, M., H. Li, W.-P. Pan, W. G. Lloyd & B. H. Davis 1996. Thermal Studies of Metal Promoted Sulfated Zirconia. *PREPRINTS OF PAPERS-AMERICAN CHEMICAL SOCIETY DIVISION FUEL CHEMISTRY* **41**: 77-81.
- Biesinger, M. C., B. P. Payne, A. P. Grosvenor, L. W. Lau, A. R. Gerson & R. S. C. Smart 2011. Resolving surface chemical states in XPS analysis of first row transition metals, oxides and hydroxides: Cr, Mn, Fe, Co and Ni. *Applied Surface Science* **257**(7): 2717-2730.
- Bijker, N., P. Meijnen, J. L. Peterse, J. Bogaerts, I. Van Hoorebeeck, J.-P. Julien, M. Gennaro, P. Rouanet, A. Avril & I. S. Fentiman 2006. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. *Journal of Clinical Oncology* **24**(21): 3381-3387.
- Blanks, R., S. Moss, C. McGahan, M. Quinn & P. Babb 2000. Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990-8: comparison of observed with predicted mortality. *Bmj* **321**(7262): 665-669.

- Bosch, F. X., J. Ribes, M. Díaz & R. Cléries 2004. Primary liver cancer: worldwide incidence and trends. *Gastroenterology* **127**(5): S5-S16.
- Boschini, F., B. Robertz, A. Rulmont & R. Cloots 2003. Preparation of nanosized barium zirconate powder by thermal decomposition of urea in an aqueous solution containing barium and zirconium, and by calcination of the precipitate. *Journal of the European Ceramic Society* **23**(16): 3035-3042.
- Bosset, J.-F., G. Calais, L. Mineur, P. Maingon, L. Radosevic-Jelic, A. Daban, E. Bardet, A. Beny, A. Briffaux & L. Collette 2005. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results—EORTC 22921. *Journal of Clinical Oncology* **23**(24): 5620-5627.
- Bouvard, V., R. Baan, K. Straif, Y. Grosse, B. Secretan, F. E. Ghissassi, L. Benbrahim-Tallaa, N. Guha, C. Freeman & L. Galichet 2009. A review of human carcinogens—Part B: biological agents. *The lancet oncology* **10**(4): 321-322.
- Bowers, D. C., Y. Liu, W. Leisenring, E. McNeil, M. Stovall, J. G. Gurney, L. L. Robison, R. J. Packer & K. C. Oeffinger 2006. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. *Journal of Clinical Oncology* **24**(33): 5277-5282.
- Bowker, S. L., S. R. Majumdar, P. Veugelers & J. A. Johnson 2006. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. *Diabetes care* **29**(2): 254-258.
- Brabec, V. 2002. DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair. *Progress in nucleic acid research and molecular biology* **71**: 1-68.
- Brabec, V. & O. Nováková 2006. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity. *Drug Resistance Updates* **9**(3): 111-122.
- Brandes, J. A., E. Ingall & D. Paterson 2007. Characterization of minerals and organic phosphorus species in marine sediments using soft X-ray fluorescence spectromicroscopy. *Marine Chemistry* **103**(3): 250-265.
- Brannon-Peppas, L. & J. O. Blanchette 2012. Nanoparticle and targeted systems for cancer therapy. *Advanced drug delivery reviews* **64**: 206-212.
- Briggs, D. & J. T. Grant. 2003. Surface analysis by Auger and X-ray photoelectron spectroscopy Ed.: IM publications.
- Brown, A. C. & J. J. Hargreaves 1999. Sulfated metal oxide catalysts. Superactivity through superacidity? *Green Chemistry* **1**(1): 17-20.
- Bruce, W. R., A. Giacca & A. Medline 2000. Possible mechanisms relating diet and risk of colon cancer. *Cancer Epidemiology Biomarkers & Prevention* **9**(12): 1271-1279.

- Burger, H., W. J. Loos, K. Eechout, J. Verweij, R. H. Mathijssen & E. A. Wiemer 2011. Drug transporters of platinum-based anticancer agents and their clinical significance. *Drug Resistance Updates* **14**(1): 22-34.
- Butler, L., R. Sinha, R. Millikan, C. Martin, B. Newman, M. Gammon, A. Ammerman & R. Sandler 2003. Heterocyclic amines, meat intake, and association with colon cancer in a population-based study. *American journal of epidemiology* **157**(5): 434-445.
- Butt, H.-J., B. Cappella & M. Kappl 2005. Force measurements with the atomic force microscope: Technique, interpretation and applications. *Surface science reports* **59**(1): 1-152.
- Cao, D., S. Guo, R. W. Allan, K. H. Molberg & Y. Peng 2009. SALL4 is a novel sensitive and specific marker of ovarian primitive germ cell tumors and is particularly useful in distinguishing yolk sac tumor from clear cell carcinoma. *The American journal of surgical pathology* **33**(6): 894-904.
- Cao, G. 2004. Synthesis, Properties and Applications Ed.: World Scientific.
- Carlson, C., S. M. Hussain, A. M. Schrand, L. K. Braydich-Stolle, K. L. Hess, R. L. Jones & J. J. Schlager 2008. Unique cellular interaction of silver nanoparticles: size-dependent generation of reactive oxygen species. *The journal of physical chemistry B* **112**(43): 13608-13619.
- Carmichael, A. R. & T. Bates 2004. Obesity and breast cancer: a review of the literature. *The Breast* **13**(2): 85-92.
- Carniti, P., A. Gervasini & M. Marzo 2011. Absence of expected side-reactions in the dehydration reaction of fructose to HMF in water over niobic acid catalyst. *Catalysis Communications* **12**(12): 1122-1126.
- Caturelli, E., G. Ghittoni, T. Ranalli & V. Gomes 2014. Nodular regenerative hyperplasia of the liver: coral atoll-like lesions on ultrasound are characteristic in predisposed patients. *The British journal of radiology*.
- Chang, P. R., R. Jian, P. Zheng, J. Yu & X. Ma 2010. Preparation and properties of glycerol plasticized-starch (GPS)/cellulose nanoparticle (CN) composites. *Carbohydrate Polymers* **79**(2): 301-305.
- Chen, W. Y., B. Rosner, S. E. Hankinson, G. A. Colditz & W. C. Willett 2011. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. *Jama* **306**(17): 1884-1890.
- Cheng, Z., H. Yang, L. Yu, Y. Cui & S. Feng 2006. Preparation and magnetic properties of Y<sub>3</sub>Fe<sub>5</sub>O<sub>12</sub> nanoparticles doped with the gadolinium oxide. *Journal of magnetism and magnetic materials* **302**(1): 259-262.
- Chinnaiyan, A. M., U. Prasad, S. Shankar, D. A. Hamstra, M. Shanaiah, T. L. Chenevert, B. D. Ross & A. Rehemtulla 2000. Combined effect of tumor

necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. *Proceedings of the National Academy of Sciences* **97**(4): 1754-1759.

- Chizallet, C. & P. Raybaud 2009. Pseudo-Bridging Silanols as Versatile Brønsted Acid Sites of Amorphous Aluminosilicate Surfaces. *Angewandte Chemie International Edition* **48**(16): 2891-2893.
- Choi, O. & Z. Hu 2008. Size dependent and reactive oxygen species related nanosilver toxicity to nitrifying bacteria. *Environmental science & technology* **42**(12): 4583-4588.
- Chopra, S., K. Dinshaw, R. Kamble & R. Sarin 2014. Breast movement during normal and deep breathing, respiratory training and set up errors: implications for external beam partial breast irradiation. *The British journal of radiology*.
- Chopra, S., F. Ors & D. Bergin 2014. MRI of angiosarcoma associated with chronic lymphoedema: Stewart-Treves syndrome. *The British journal of radiology*.
- Chu, E. & V. T. DeVita. 2006. Physicians' cancer chemotherapy drug manual 2006 Ed.: Jones & Bartlett Learning.
- Ciarimboli, G. 2014. Membrane transporters as mediators of cisplatin side-effects. *Anticancer research* **34**(1): 547-550.
- Clark, J. H. 2002. Solid acids for green chemistry. *Accounts of chemical research* **35**(9): 791-797.
- Clearfield, A., G. Serrette & A. Khazi-Syed 1994. Nature of hydrous zirconia and sulfated hydrous zirconia. *Catalysis today* **20**(2): 295-312.
- Cohen, G. M. 1997. Caspases: the executioners of apoptosis. *Biochemical Journal* **326**(1): 1-16.
- Coleman, R. 2001. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. *Cancer treatment reviews* **27**(3): 165-176.
- Costa, C. S., J. V. V. Ronconi, J. F. Daufenbach, C. L. Gonçalves, G. T. Rezin, E. L. Streck & M. M. da Silva Paula 2010. In vitro effects of silver nanoparticles on the mitochondrial respiratory chain. *Molecular and cellular biochemistry* **342**(1-2): 51-56.
- Crabtree, R. H. 2009. The organometallic chemistry of the transition metals Ed.: John Wiley & Sons.
- Cui, X., Y. Jin, A. B. Hofseth, E. Pena, J. Habiger, A. Chumanevich, D. Poudyal, M. Nagarkatti, P. S. Nagarkatti & U. P. Singh 2010. Resveratrol suppresses colitis and colon cancer associated with colitis. *Cancer Prevention Research* **3**(4): 549-559.

- Dan, H. C., M. Sun, S. Kaneko, R. I. Feldman, S. V. Nicosia, H.-G. Wang, B. K. Tsang & J. Q. Cheng 2004. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). *Journal of Biological Chemistry* **279**(7): 5405-5412.
- Das, R. K., N. Kasoju & U. Bora 2010. Encapsulation of curcumin in alginate-chitosan-pluronic composite nanoparticles for delivery to cancer cells. *Nanomedicine: Nanotechnology, Biology and Medicine* **6**(1): 153-160.
- Dasari, S. & P. B. Tchounwou 2014. Cisplatin in cancer therapy: molecular mechanisms of action. *European journal of pharmacology* **740**: 364-378.
- Date, A. A. & V. Patravale 2004. Current strategies for engineering drug nanoparticles. *Current opinion in colloid & interface science* **9**(3-4): 222-235.
- de González, A. B. & S. Darby 2004. Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. *The Lancet* **363**(9406): 345-351.
- de Oliveira, C., K. E. Bremner, R. Pataky, N. Gunraj, K. Chan, S. Peacock & M. D. Krahn 2013. Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study. *Canadian Medical Association Open Access Journal* **1**(1): E1-E8.
- Delahay, G., E. Ensuque, B. Coq & F. Figueras 1998. Selective Catalytic Reduction of Nitric Oxide by Decane on Cu/Sulfated-Zirconia Catalysts in Oxygen Rich Atmosphere: Effect of Sulfur and Copper Contents. *Journal of Catalysis* **175**(1): 7-15.
- Derelanko, M. J. & C. S. Auletta. 2014. Handbook of toxicology Ed.: CRC press.
- DeSantis, C., J. Ma, L. Bryan & A. Jemal 2014. Breast cancer statistics, 2013. *CA: a cancer journal for clinicians* **64**(1): 52-62.
- DeSantis, C. E., C. C. Lin, A. B. Mariotto, R. L. Siegel, K. D. Stein, J. L. Kramer, R. Alteri, A. S. Robbins & A. Jemal 2014. Cancer treatment and survivorship statistics, 2014. *CA: a cancer journal for clinicians* **64**(4): 252-271.
- Deveraux, Q. L., E. Leo, H. R. Stennicke, K. Welsh, G. S. Salvesen & J. C. Reed 1999. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. *The EMBO journal* **18**(19): 5242-5251.
- Deveraux, Q. L., R. Takahashi, G. S. Salvesen & J. C. Reed 1997. X-linked IAP is a direct inhibitor of cell-death proteases. *Nature* **388**(6639): 300-304.
- Dimeo, F. C., R. D. Stieglitz, U. Novelli-Fischer, S. Fetscher & J. Keul 1999. Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy. *Cancer* **85**(10): 2273-2277.
- Dincer, F., O. Akgol, M. Karaaslan, E. Unal & C. Sabah 2014. Polarization angle independent perfect metamaterial absorbers for solar cell applications in the

microwave, infrared, and visible regime. *Progress In Electromagnetics Research* **144**: 93-101.

- Dogan, A. U., M. Dogan, M. Onal, Y. Sarikaya, A. Aburub & D. E. Wurster 2006. Baseline studies of the clay minerals society source clays: specific surface area by the Brunauer Emmett Teller (BET) method. *Clays and Clay Minerals* **54**(1): 62-66.
- Dong, S., C. Han, B. Zheng, M. Zhang & F. Huang 2012. Preparation of two new [2] rotaxanes based on the pillar [5] arene/alkane recognition motif. *Tetrahedron Letters* **53**(28): 3668-3671.
- Doroshow, J. H. 2006. Redox modulation of chemotherapy-induced tumor cell killing and normal tissue toxicity. *Journal of the National Cancer Institute* **98**(4): 223-225.
- Drofenik, M., D. Lisjak & D. Makovec 2005. The synthesis and properties of magnetic nanoparticles. *Materials Science Forum*. **494** pp. 129-136.
- Du, C., M. Fang, Y. Li, L. Li & X. Wang 2000. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. *Cell* **102**(1): 33-42.
- Du, Y., K. Wang, H. Fang, J. Li, D. Xiao, P. Zheng, Y. Chen, H. Fan, X. Pan & C. Zhao 2006. Coordination of intrinsic, extrinsic, and endoplasmic reticulum-mediated apoptosis by imatinib mesylate combined with arsenic trioxide in chronic myeloid leukemia. *Blood* **107**(4): 1582-1590.
- Dukas, L., W. C. Willett, G. A. Colditz, C. S. Fuchs, B. Rosner & E. L. Giovannucci 2000. Prospective study of bowel movement, laxative use, and risk of colorectal cancer among women. *American journal of epidemiology* **151**(10): 958-964.
- Earnshaw, W. C., L. M. Martins & S. H. Kaufmann 1999. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. *Annual review of biochemistry* **68**(1): 383-424.
- Ecormier, M. A., K. Wilson & A. F. Lee 2003. Structure-reactivity correlations in sulphated-zirconia catalysts for the isomerisation of  $\alpha$ -pinene. *Journal of Catalysis* **215**(1): 57-65.
- El-Serag, H. B. & K. L. Rudolph 2007. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology* **132**(7): 2557-2576.
- Evans, P., R. Stevens & J. Binner 1984. Quantitative X-ray diffraction analysis of polymorphic mixes of pure zirconia.
- Feldman, M., L. S. Friedman & L. J. Brandt. 2015. Sleisenger and Fordtran's gastrointestinal and liver disease: pathophysiology, diagnosis, management Ed.: Elsevier Health Sciences.

- Ferlay, J., I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D. M. Parkin, D. Forman & F. Bray 2015. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *International Journal of Cancer* **136**(5): E359-E386.
- Fesik, S. W. 2005. Promoting apoptosis as a strategy for cancer drug discovery. *Nature Reviews Cancer* **5**(11): 876-885.
- Fisher, B., S. Land, E. Mamounas, J. Dignam, E. R. Fisher & N. Wolmark 2001. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. *Seminars in oncology*. **28** pp. 400-418.
- Fletcher, S. W. & J. G. Elmore 2003. Mammographic screening for breast cancer. *New England Journal of Medicine* **348**(17): 1672-1680.
- Flores, A. & J. A. Marrero 2014. Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. *Clinical Medicine Insights. Oncology* **8**: 71.
- Foldbjerg, R., P. Olesen, M. Hougaard, D. A. Dang, H. J. Hoffmann & H. Autrup 2009. PVP-coated silver nanoparticles and silver ions induce reactive oxygen species, apoptosis and necrosis in THP-1 monocytes. *Toxicology letters* **190**(2): 156-162.
- Ford, D., D. Easton, M. Stratton, S. Narod, D. Goldgar, P. Devilee, D. Bishop, B. Weber, G. Lenoir & J. Chang-Claude 1998. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. *The American Journal of Human Genetics* **62**(3): 676-689.
- Fornage, B. D., N. Sneige, M. I. Ross, A. N. Mirza, H. M. Kuerer, B. S. Edeiken, F. C. Ames, L. A. Newman, G. V. Babiera & S. E. Singletary 2004. Small ( $\leq$  2-cm) Breast Cancer Treated with US-guided Radiofrequency Ablation: Feasibility Study 1. *Radiology* **231**(1): 215-224.
- Freudenheim, J. L., J. R. Marshall, J. E. Vena, R. Laughlin, J. R. Brasuré, M. K. Swanson, T. Nemoto & S. Graham 1996. Premenopausal breast cancer risk and intake of vegetables, fruits, and related nutrients. *Journal of the National Cancer Institute* **88**(6): 340-348.
- Friedl, P. & K. Wolf 2003. Tumour-cell invasion and migration: diversity and escape mechanisms. *Nature Reviews Cancer* **3**(5): 362-374.
- Fu, P. P., Q. Xia, H.-M. Hwang, P. C. Ray & H. Yu 2014. Mechanisms of nanotoxicity: generation of reactive oxygen species. *Journal of food and drug analysis* **22**(1): 64-75.
- Fulda, S. & K. Debatin 2006. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. *Oncogene* **25**(34): 4798-4811.

- Garcia, A., S. Erdman, S. Xu, Y. Feng, A. Rogers, M. Schrenzel, J. Murphy & J. Fox 2002. Hepatobiliary inflammation, neoplasia, and argyrophilic bacteria in a ferret colony. *Veterinary Pathology Online* **39**(2): 173-179.
- Gardner, R. P. & W. Guo 2005. Development of a Monte Carlo—Library Least-Squares code package for the EDXRF inverse problem. *Powder diffraction* **20**(02): 146-152.
- Garvie, R. & M. Goss 1986. Intrinsic size dependence of the phase transformation temperature in zirconia microcrystals. *Journal of materials science* **21**(4): 1253-1257.
- Garvie, R. C. & P. S. Nicholson 1972. Phase analysis in zirconia systems. *Journal of the American Ceramic Society* **55**(6): 303-305.
- Glorius, F. & S. Bellemin-Laponnaz. 2007. N-heterocyclic carbenes in transition metal catalysis Ed.: Springer Science & Business Media.
- Goldhirsch, A., W. Wood, A. Coates, R. Gelber, B. Thürlimann & H.-J. Senn 2011. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. *Annals of oncology*: mdr304.
- Golosio, B., A. Simionovici, A. Somogyi, L. Lemelle, M. Chukalina & A. Brunetti 2003. Internal elemental microanalysis combining X-ray fluorescence, Compton and transmission tomography. *Journal of applied physics* **94**(1): 145-156.
- Gonzalvez, F. & A. Ashkenazi 2010. New insights into apoptosis signaling by Apo2L/TRAIL. *Oncogene* **29**(34): 4752-4765.
- Grant, W. B. 2012. Role of solar UVB irradiance and smoking in cancer as inferred from cancer incidence rates by occupation in Nordic countries. *Dermato-endocrinology* **4**(2): 203-211.
- Grass, G., C. Rensing & M. Solioz 2011. Metallic copper as an antimicrobial surface. *Applied and environmental microbiology* **77**(5): 1541-1547.
- Greeley, J., I. Stephens, A. Bondarenko, T. P. Johansson, H. A. Hansen, T. Jaramillo, J. Rossmeisl, I. Chorkendorff & J. K. Nørskov 2009. Alloys of platinum and early transition metals as oxygen reduction electrocatalysts. *Nature chemistry* **1**(7): 552-556.
- Green, D. R. & J. C. Reed 1998. Mitochondria and apoptosis. *Science* **281**(5381): 1309.
- Group, E. B. C. T. C. 1990. Treatment of early breast cancer. 1. Worldwide evidence 1985-1990 Ed. 1. Oxford University Press, USA.
- Gupta, A. K. & M. Gupta 2005. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. *Biomaterials* **26**(18): 3995-4021.

- Gustafson, J., M. Shipilin, C. Zhang, A. Stierle, U. Hejral, U. Ruett, O. Gutowski, P.-A. Carlsson, M. Skoglundh & E. Lundgren 2014. High-energy surface X-ray diffraction for fast surface structure determination. *Science* **343**(6172): 758-761.
- Haeger, A., M. Krause, K. Wolf & P. Friedl 2014. Cell jamming: collective invasion of mesenchymal tumor cells imposed by tissue confinement. *Biochimica et Biophysica Acta (BBA)-General Subjects* **1840**(8): 2386-2395.
- Hafner, A. & S. Braese 2011. Efficient Trifluoromethylation of Activated and Non-Activated Alkenyl Halides by Using (Trifluoromethyl) trimethylsilane. *Advanced Synthesis & Catalysis* **353**(16): 3044-3048.
- Hall, E. & D. Brenner 2014. Cancer risks from diagnostic radiology. *The British journal of radiology*.
- Hansen, J. 2001. Increased breast cancer risk among women who work predominantly at night. *Epidemiology* **12**(1): 74-77.
- Hashibe, M., P. Brennan, S. Benhamou, X. Castellsague, C. Chen, M. P. Curado, L. Dal Maso, A. W. Daudt, E. Fabianova & V. Wünsch-Filho 2007. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. *Journal of the National Cancer Institute* **99**(10): 777-789.
- Henkart, P. A. & S. Grinstein 1996. Apoptosis: mitochondria resurrected? *The Journal of experimental medicine* **183**(4): 1293-1295.
- Herzog, C. E., R. J. Andrassy & F. Eftekhari 2000. Childhood cancers: hepatoblastoma. *The oncologist* **5**(6): 445-453.
- Hoet, P. H., I. Brüske-Hohlfeld & O. V. Salata 2004. Nanoparticles-known and unknown health risks. *Journal of nanobiotechnology* **2**(1): 12.
- Holick, M. F. 2004. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. *The American journal of clinical nutrition* **80**(6): 1678S-1688S.
- Hong, J. S. & J. Tian 2014. Prevalence of anxiety and depression and their risk factors in Chinese cancer patients. *Supportive Care in Cancer* **22**(2): 453-459.
- Hongxi, X., S. Kaikai, L. Yuanzhi, T. Hongsheng, K. Chen, D. Yang, S. Chen, B. Zhaoxiang, L. Chengyuan & L. Aiping 2015. Usage of guttiferone k for treating high metastatic cancer, Google Patents.
- Huang, Q., F. Li, X. Liu, W. Li, W. Shi, F.-F. Liu, B. O'Sullivan, Z. He, Y. Peng & A.-C. Tan 2011. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. *Nature medicine* **17**(7): 860-866.

- Hubbell, J., P. Trehan, N. Singh, B. Chand, D. Mehta, M. Garg, R. Garg, S. Singh & S. Puri 1994. A Review, Bibliography, and Tabulation of K, L, and Higher Atomic Shell X-Ray Fluorescence Yields. *Journal of physical and chemical reference data* **23**(2): 339-364.
- Humphrey, L. L., M. Helfand, B. K. Chan & S. H. Woolf 2002. Breast cancer screening: a summary of the evidence for the US Preventive Services Task Force. *Annals of internal medicine* **137**(5\_Part\_1): 347-360.
- Hunter, R. J. 2013. Zeta potential in colloid science: principles and applications Ed. 2. Academic press.
- Istone, W. K. 1995. X-Ray photoelectron spectroscopy (XPS) Ed.: CRC Press.
- Jain, K. K. 2014. Drug delivery system Ed.: Springer.
- Jain, S., D. Hirst & J. O'sullivan 2014. Gold nanoparticles as novel agents for cancer therapy. *The British journal of radiology*.
- Janssens, K., K. Proost & G. Falkenberg 2004. Confocal microscopic X-ray fluorescence at the HASYLAB microfocus beamline: characteristics and possibilities. *Spectrochimica Acta Part B: Atomic Spectroscopy* **59**(10): 1637-1645.
- Jemal, A., F. Bray, M. M. Center, J. Ferlay, E. Ward & D. Forman 2011. Global cancer statistics. *CA: a cancer journal for clinicians* **61**(2): 69-90.
- Jemal, A., T. Murray, E. Ward, A. Samuels, R. C. Tiwari, A. Ghafoor, E. J. Feuer & M. J. Thun 2005. Cancer statistics, 2005. *CA: a cancer journal for clinicians* **55**(1): 10-30.
- Jentoft, F. C., A. Hahn, J. Kröhnert, G. Lorenz, R. E. Jentoft, T. Ressler, U. Wild, R. Schlögl, C. Häßner & K. Köhler 2004. Incorporation of manganese and iron into the zirconia lattice in promoted sulfated zirconia catalysts. *Journal of Catalysis* **224**(1): 124-137.
- Jessup, J. M., A. Stewart, F. L. Greene & B. D. Minsky 2005. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. *Jama* **294**(21): 2703-2711.
- Ji, Q., X. Hao, M. Zhang, W. Tang, M. Yang, L. Li, D. Xiang, J. T. DeSano, G. T. Bommer & D. Fan 2009. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. *PloS one* **4**(8): e6816.
- Jia, X., W. Yang, M. Qin & J. Li 2009. Structure and magnetism in Mn-doped zirconia: Density-functional theory studies. *Journal of magnetism and magnetic materials* **321**(15): 2354-2358.
- Jin, Y., Z. Desta, V. Stearns, B. Ward, H. Ho, K.-H. Lee, T. Skaar, A. M. Storniolo, L. Li & A. Araba 2005. CYP2D6 genotype, antidepressant use, and tamoxifen

metabolism during adjuvant breast cancer treatment. *Journal of the National Cancer Institute* **97**(1): 30-39.

Jogalekar, A., R. Jaiswal & R. Jayaram 1998. Activity of modified SnO<sub>2</sub> catalysts for acid-catalysed reactions. *Journal of Chemical Technology and Biotechnology* **71**(3): 234-240.

Jones, J., C. Brenner, R. Chinn & C. Bunker 2014. Radiological associations with dermatological disease. *The British journal of radiology*.

Joo, S. H., S. J. Choi, I. Oh, J. Kwak, Z. Liu, O. Terasaki & R. Ryoo 2001. Ordered nanoporous arrays of carbon supporting high dispersions of platinum nanoparticles. *Nature* **412**(6843): 169-172.

Kai, L., Z. Wang, W. Yao, K. Dong & X. Xiao 2014. Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma. *Journal of cancer research and clinical oncology* **140**(3): 471-476.

Kalidindi, S. B., M. Indirani & B. R. Jagirdar 2008. First row transition metal ion-assisted ammonia– borane hydrolysis for hydrogen generation. *Inorganic chemistry* **47**(16): 7424-7429.

Kašpar, J. & P. Fornasiero 2003. Nanostructured materials for advanced automotive de-pollution catalysts. *Journal of Solid State Chemistry* **171**(1): 19-29.

Katada, N., J.-i. Endo, K.-i. Notsu, N. Yasunobu, N. Naito & M. Niwa 2000. Superacidity and catalytic activity of sulfated zirconia. *The Journal of Physical Chemistry B* **104**(44): 10321-10328.

Kaufmann, T., A. Strasser & P. Jost 2012. Fas death receptor signalling: roles of Bid and XIAP. *Cell Death & Differentiation* **19**(1): 42-50.

Kelsey, J. L. 1993. Breast cancer epidemiology: summary and future directions. *Epidemiologic Reviews* **15**(1): 256-263.

Kennecke, H., R. Yerushalmi, R. Woods, M. C. U. Cheang, D. Voduc, C. H. Speers, T. O. Nielsen & K. Gelmon 2010. Metastatic behavior of breast cancer subtypes. *Journal of Clinical Oncology* **28**(20): 3271-3277.

Key, T. J., P. K. Verkasalo & E. Banks 2001. Epidemiology of breast cancer. *The lancet oncology* **2**(3): 133-140.

Khalaf, H. A. 2009. Textural properties of sulfated iron hydroxide promoted with aluminum. *Monatshefte für Chemie/Chemical Monthly* **140**(6): 669-674.

Khan, F. M. & J. P. Gibbons. 2014. Khan's the Physics of Radiation Therapy Ed.: Lippincott Williams & Wilkins.

- Khder, A., E. El-Sharkawy, S. El-Hakam & A. Ahmed 2008. Surface characterization and catalytic activity of sulfated tin oxide catalyst. *Catalysis Communications* **9**(5): 769-777.
- Kindblom, L.-G., H. E. Remotti, F. Aldenborg & J. M. Meis-Kindblom 1998. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. *The American journal of pathology* **152**(5): 1259.
- Klockenkämper, R. & A. von Bohlen. 2014. Total-Reflection X-Ray Fluorescence Analysis and Related Methods Ed.: John Wiley & Sons.
- Kneipp, J., P. Lasch, E. Baldauf, M. Beekes & D. Naumann 2000. Detection of pathological molecular alterations in scrapie-infected hamster brain by Fourier transform infrared (FT-IR) spectroscopy. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease* **1501**(2): 189-199.
- Kondo, T. & C. Sawatari 1996. A Fourier transform infra-red spectroscopic analysis of the character of hydrogen bonds in amorphous cellulose. *Polymer* **37**(3): 393-399.
- Krieg, A. M. 2002. CPG motifs in bacterial dna and their immune effects\*. *Annual review of immunology* **20**(1): 709-760.
- Krieg, A. M. & H. Wagner 2000. Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. *Immunology today* **21**(10): 521-526.
- Kuebler, J. P., H. S. Wieand, M. J. O'Connell, R. E. Smith, L. H. Colangelo, G. Yothers, N. J. Petrelli, M. P. Findlay, T. E. Seay & J. N. Atkins 2007. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. *Journal of Clinical Oncology* **25**(16): 2198-2204.
- Kuhn, J. N., W. Huang, C.-K. Tsung, Y. Zhang & G. A. Somorjai 2008. Structure sensitivity of carbon– nitrogen ring opening: impact of platinum particle size from below 1 to 5 nm upon pyrrole hydrogenation product selectivity over monodisperse platinum nanoparticles loaded onto mesoporous silica. *Journal of the American Chemical Society* **130**(43): 14026-14027.
- Kumar, C. S. 2007. Nanomaterials for cancer diagnosis Ed. 3. Wiley-VCH Weinheim, Germany.
- Kumar, D., V. B. Reddy, B. G. Mishra, R. Rana, M. N. Nadagouda & R. S. Varma 2007. Nanosized magnesium oxide as catalyst for the rapid and green synthesis of substituted 2-amino-2-chromenes. *Tetrahedron* **63**(15): 3093-3097.
- Kvåle, G. & I. Heuch 1988. Menstrual factors and breast cancer risk. *Cancer* **62**(8): 1625-1631.

- Larsson, S. & A. Wolk 2012. Red and processed meat consumption and risk of pancreatic cancer: meta-analysis of prospective studies. *British journal of cancer* **106**(3): 603-607.
- Lawrence, M. S., P. Stojanov, C. H. Mermel, J. T. Robinson, L. A. Garraway, T. R. Golub, M. Meyerson, S. B. Gabriel, E. S. Lander & G. Getz 2014. Discovery and saturation analysis of cancer genes across 21 tumour types. *Nature* **505**(7484): 495-501.
- Le Voyer, T., E. Sigurdson, A. Hanlon, R. Mayer, J. Macdonald, P. Catalano & D. Haller 2003. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. *Journal of Clinical Oncology* **21**(15): 2912-2919.
- Lee, D.-H., K. E. Anderson, L. J. Harnack, A. R. Folsom & D. R. Jacobs 2004. Heme iron, zinc, alcohol consumption, and colon cancer: Iowa Women's Health Study. *Journal of the National Cancer Institute* **96**(5): 403-407.
- Leemans, C. R., B. J. Braakhuis & R. H. Brakenhoff 2011. The molecular biology of head and neck cancer. *Nature Reviews Cancer* **11**(1): 9-22.
- Lewis, J. H., M. L. Kilgore, D. P. Goldman, E. L. Trimble, R. Kaplan, M. J. Montello, M. G. Housman & J. J. Escarce 2003. Participation of patients 65 years of age or older in cancer clinical trials. *Journal of Clinical Oncology* **21**(7): 1383-1389.
- Lewis, S. L., S. R. Dirksen, M. M. Heitkemper & L. Bucher. 2014. Medical-Surgical Nursing: Assessment and Management of Clinical Problems, Single Volume Ed.: Elsevier Health Sciences.
- Li, C. I., B. O. Anderson, J. R. Daling & R. E. Moe 2003. Trends in incidence rates of invasive lobular and ductal breast carcinoma. *Jama* **289**(11): 1421-1424.
- Li, Y. & G. A. Somorjai 2010. Nanoscale advances in catalysis and energy applications. *Nano letters* **10**(7): 2289-2295.
- Li, Y., W. Zhang, J. Niu & Y. Chen 2012. Mechanism of photogenerated reactive oxygen species and correlation with the antibacterial properties of engineered metal-oxide nanoparticles. *Acs Nano* **6**(6): 5164-5173.
- Liao, C., C. Wu & Y. Yan 2007. The characteristics of inorganic elements in ashes from a 1 MW CFB biomass gasification power generation plant. *Fuel processing technology* **88**(2): 149-156.
- Liao, L., J. Liu, E. C. Dreaden, S. W. Morton, K. E. Shopsowitz, P. T. Hammond & J. A. Johnson 2014. A convergent synthetic platform for single-nanoparticle combination cancer therapy: ratiometric loading and controlled release of cisplatin, doxorubicin, and camptothecin. *Journal of the American Chemical Society* **136**(16): 5896-5899.

- Lieberman, D. A. 2009. Screening for colorectal cancer. *New England Journal of Medicine* **361**(12): 1179-1187.
- Lippert, B. 1999. Cisplatin: chemistry and biochemistry of a leading anticancer drug Ed.: Helvetica Chimica Acta.
- Litten, J. B. & G. E. Tomlinson 2008. Liver tumors in children. *The oncologist* **13**(7): 812-820.
- Liu, C., J. Wang & Y. Li 2006. One-pot synthesis of 3, 4-dihydropyrimidin-2 (1H)-(thio) ones using strontium (II) nitrate as a catalyst. *Journal of Molecular Catalysis A: Chemical* **258**(1): 367-370.
- Liu, D.-W., Y.-P. Tsao, J. T. Kung, Y.-A. Ding, H.-K. Sytwu, X. Xiao & S.-L. Chen 2000. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. *Journal of virology* **74**(6): 2888-2894.
- Liu, K., T. Schmedake & R. Tsu 2008. A comparative study of colloidal silica spheres: Photonic crystals versus Bragg's law. *Physics Letters A* **372**(24): 4517-4520.
- Liu, R. H. 2004. Potential synergy of phytochemicals in cancer prevention: mechanism of action. *The Journal of nutrition* **134**(12): 3479S-3485S.
- Liu, X., C. N. Kim, J. Yang, R. Jemmerson & X. Wang 1996. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. *Cell* **86**(1): 147-157.
- Liu, Y., Z. Dang, Y. Wang, J. Huang & H. Li 2014. Hydroxyapatite/graphene-nanosheet composite coatings deposited by vacuum cold spraying for biomedical applications: Inherited nanostructures and enhanced properties. *Carbon* **67**: 250-259.
- Liu, Z. & P. J. Sadler 2014. Organoiridium complexes: anticancer agents and catalysts. *Accounts of chemical research* **47**(4): 1174-1185.
- LoBiondo-Wood, G. & J. Haber. 2014. Nursing research: Methods and critical appraisal for evidence-based practice Ed.: Elsevier Health Sciences.
- Love, S. M. & S. H. Barsky 2004. Anatomy of the nipple and breast ducts revisited. *Cancer* **101**(9): 1947-1957.
- Ma, C.-H., J.-H. Huang & H. Chen 2002. Residual stress measurement in textured thin film by grazing-incidence X-ray diffraction. *Thin Solid Films* **418**(2): 73-78.
- Mahmoudi, M., S. Laurent, M. A. Shokrgozar & M. Hosseinkhani 2011. Toxicity evaluations of superparamagnetic iron oxide nanoparticles: cell "vision" versus physicochemical properties of nanoparticles. *ACS nano* **5**(9): 7263-7276.

- Mak, C., C. Chou, C. Su, S. Huan & J. Chang 2014. Ultrasound diagnosis of paratesticular rhabdomyosarcoma. *The British journal of radiology*.
- Mansel, R. E., L. Fallowfield, M. Kissin, A. Goyal, R. G. Newcombe, J. M. Dixon, C. Yangou, K. Horgan, N. Bundred & I. Monypenny 2006. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. *Journal of the National Cancer Institute* **98**(9): 599-609.
- Marcus, J. N., P. Watson, D. L. Page, S. A. Narod, G. M. Lenoir, P. Tonin, L. Linder-Stephenson, G. Salerno, T. A. Conway & H. T. Lynch 1996. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. *Cancer* **77**(4): 697-709.
- Marks, P. A., R. A. Rifkind, V. M. Richon, R. Breslow, T. Miller & W. K. Kelly 2001. Histone deacetylases and cancer: causes and therapies. *Nature Reviews Cancer* **1**(3): 194-202.
- Marr, G. V. 2013. Handbook on Synchrotron Radiation: Vacuum Ultraviolet and Soft X-ray Processes Ed. 2. Elsevier.
- Marsden, V. S., L. O'Connor, L. A. O'Reilly, J. Silke, D. Metcalf, P. G. Ekert, D. C. Huang, F. Cecconi, K. Kuida & K. J. Tomaselli 2002. Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. *Nature* **419**(6907): 634-637.
- Marshall, J. L., R. J. Hoyer, M. A. Toomey, K. Faraguna, P. Chang, E. Richmond, J. E. Pedicano, E. Gehan, R. A. Peck & P. Arlen 2000. Phase I Study in Advanced Cancer Patients of a Diversified Prime-and-Boost Vaccination Protocol Using Recombinant Vaccinia Virus and Recombinant Nonreplicating Avipox Virus to Elicit Anti-Carcinoembryonic Antigen Immune Responses. *Journal of Clinical Oncology* **18**(23): 3964-3973.
- Marx, J. 2003. Mutant stem cells may seed cancer. *Science* **301**(5638): 1308.
- Maynard, A. D. 2007. Nanotechnology: the next big thing, or much ado about nothing? *Annals of Occupational Hygiene* **51**(1): 1-12.
- Maynard, A. D., R. J. Aitken, T. Butz, V. Colvin, K. Donaldson, G. Oberdörster, M. A. Philbert, J. Ryan, A. Seaton & V. Stone 2006. Safe handling of nanotechnology. *Nature* **444**(7117): 267-269.
- Meghshyam, K. 2009. Synthesis of novel zirconia based solid superacids their characterization and application in organic synthesis and transofrmation reactions.Tesis Osmania University,
- Meijers-Heijboer, H., A. van den Ouwehand, J. Klijn, M. Wasielewski, A. de Snoo, R. Oldenburg, A. Hollestelle, M. Houben, E. Crepin & M. van Veghel-Plandsoen 2002. Low-penetrance susceptibility to breast cancer due to CHEK2\*

- 1100delC in noncarriers of BRCA1 or BRCA2 mutations. *Nature genetics* **31**(1): 55-59.
- Mekhemer, G. A., H. A. Khalaf, S. A. Mansour & A. K. Nohman 2005. Sulfated alumina catalysts: Consequences of sulfate content and source. *Monatshefte für Chemie/Chemical Monthly* **136**(12): 2007-2016.
- Meyerhardt, J. A., D. Niedzwiecki, D. Hollis, L. B. Saltz, R. J. Mayer, H. Nelson, R. Whittom, A. Hantel, J. Thomas & C. S. Fuchs 2008. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. *Journal of Clinical Oncology* **26**(25): 4109-4115.
- Mftah, A., F. H. Alhassan, M. S. Al-Qubaisi, M. E. El Zowalaty, T. J. Webster, M. Sheldin, A. Rasedee, Y. H. Taufiq-Yap & S. S. Rashid 2015. Physicochemical properties, cytotoxicity, and antimicrobial activity of sulphated zirconia nanoparticles. *International Journal of Nanomedicine* **10**: 765.
- Miao, J., P. Charalambous, J. Kirz & D. Sayre 1999. Extending the methodology of X-ray crystallography to allow imaging of micrometre-sized non-crystalline specimens. *Nature* **400**(6742): 342-344.
- Miller, V. A., M. G. Kris, N. Shah, J. Patel, C. Azzoli, J. Gomez, L. M. Krug, W. Pao, N. Rizvi & B. Pizzo 2004. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. *Journal of Clinical Oncology* **22**(6): 1103-1109.
- Moodley, N. 2014. Antimicrobial activity of ciprofloxacin-coated gold nanoparticles on selected pathogens. Thesis
- Morant-Miñana, M. C. 2014. Nanoparticles, Polymer-Based: Surface Modification.
- Morterra, C., G. Cerrato, F. Pinna & M. Signoretto 1995. Crystal phase, spectral features, and catalytic activity of sulfate-doped zirconia systems. *Journal of Catalysis* **157**(1): 109-123.
- Moulder, J. F., J. Chastain & R. C. King. 1992. Handbook of X-ray photoelectron spectroscopy: a reference book of standard spectra for identification and interpretation of XPS data Ed.: Perkin-Elmer Eden Prairie, MN.
- Mouridsen, H., T. Palshof, J. Patterson & L. Battersby 1978. Tamoxifen in advanced breast cancer. *Cancer treatment reviews* **5**(3): 131-141.
- Muhammad, N. & Z. Guo 2014. Metal-based anticancer chemotherapeutic agents. *Current opinion in chemical biology* **19**: 144-153.
- Murari, K., R. Siddique & K. Jain 2015. Use of waste copper slag, a sustainable material. *Journal of Material Cycles and Waste Management* **17**(1): 13-26.

- NAIK, M. A., B. G. MISHRA & A. DUBEY 2008. Combustion synthesized WO<sub>3</sub>-ZrO<sub>2</sub> nanocomposites as catalyst for the solvent-free synthesis of coumarins. *Colloids and surfaces. A, Physicochemical and engineering aspects* **317**(1-3): 234-238.
- Nasse, M. J., M. J. Walsh, E. C. Mattson, R. Reininger, A. Kajdacsy-Balla, V. Macias, R. Bhargava & C. J. Hirschmugl 2011. High-resolution Fourier-transform infrared chemical imaging with multiple synchrotron beams. *Nature methods* **8**(5): 413-416.
- Nel, A., T. Xia, L. Mädler & N. Li 2006. Toxic potential of materials at the nanolevel. *Science* **311**(5761): 622-627.
- Nelson, H., N. Petrelli, A. Carlin, J. Couture, J. Fleshman, J. Guillem, B. Miedema, D. Ota & D. Sargent 2001. Guidelines 2000 for colon and rectal cancer surgery. *Journal of the National Cancer Institute* **93**(8): 583-596.
- Network, N. C. C. 2003. Breast cancer Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network: JNCCN* **1**(2): 148.
- Neubauer, H., M. Li, R. Kuehne-Heid, A. Schneider & W. Kaiser 2014. High grade and non-high grade ductal carcinoma in situ on dynamic MR mammography: characteristic findings for signal increase and morphological pattern of enhancement. *The British journal of radiology*.
- Nicholson, D. 1999. Caspase structure, proteolytic substrates, and function during apoptotic cell death. *Cell death and differentiation* **6**(11): 1028-1042.
- Nicholson, D. W. & N. A. Thornberry 1997. Caspases: killer proteases. *Trends in biochemical sciences* **22**(8): 299-306.
- Nicolet, M. A. & S. Lau 2014. Formation and characterization of transition-metal silicides. *VLSI electronics: microstructure science* **6**: 329.
- Nida, D. L., M. S. Rahman, K. D. Carlson, R. Richards-Kortum & M. Follen 2005. Fluorescent nanocrystals for use in early cervical cancer detection. *Gynecologic oncology* **99**(3): S89-S94.
- Nie, S., Y. Xing, G. J. Kim & J. W. Simons 2007. Nanotechnology applications in cancer. *Annu. Rev. Biomed. Eng.* **9**: 257-288.
- Nielsen, T. O., F. D. Hsu, K. Jensen, M. Cheang, G. Karaca, Z. Hu, T. Hernandez-Boussard, C. Livasy, D. Cowan & L. Dressler 2004. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. *Clinical Cancer Research* **10**(16): 5367-5374.
- Nkuna, L. P. 2014. Overoxidized polypyrrole-osmium telluride quantum dots immunosensor for prostate specific antigen-A cancer biomarker.

- Nordberg, G. F., B. A. Fowler & M. Nordberg. 2014. Handbook on the Toxicology of Metals Ed.: Academic Press.
- Nordqvist, K. & V.-P. Herva 2013. Copper Use, Cultural Change and Neolithization in North-Eastern Europe (c. 5500–1800 bc). *European Journal of Archaeology* **16**(3): 401-432.
- Nussbaum, R., R. R. McInnes & H. F. Willard. 2015. Thompson & Thompson genetics in medicine Ed.: Elsevier Health Sciences.
- O'sullivan, P., A. Harris & P. Munk 2014. Radiological imaging features of non-uterine leiomyosarcoma. *The British journal of radiology*.
- O'Connell, J. B., M. A. Maggard & C. Y. Ko 2004. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. *Journal of the National Cancer Institute* **96**(19): 1420-1425.
- Okuda, K., Y. Nakanuma & M. Miyazaki 2002. Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. *Journal of gastroenterology and hepatology* **17**(10): 1049-1055.
- Olaussen, K. A., A. Dunant, P. Fouret, E. Brambilla, F. André, V. Haddad, E. Taranchon, M. Filipits, R. Pirker & H. H. Popper 2006. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. *New England Journal of Medicine* **355**(10): 983-991.
- Orvig, C. & M. J. Abrams 1999. Medicinal inorganic chemistry: introduction. *Chemical Reviews* **99**(9): 2201-2204.
- Owunari, G. U., S. I. Minakiri & O. A. Wolfe 2015. Effect of Disulfiram/Copper Gluconate Combination on Haematological Indices in Rodents. *Pharmacology & Pharmacy* **6**(01): 17.
- Parsons, D. W., T.-L. Wang, Y. Samuels, A. Bardelli, J. M. Cummins, L. DeLong, N. Silliman, J. Ptak, S. Szabo & J. K. Willson 2005. Colorectal cancer: mutations in a signalling pathway. *Nature* **436**(7052): 792-792.
- Patel, A. & S. Pathan. 2015. Introduction. Dlm. (pnyt.). Ed. *Polyoxomolybdates as Green Catalysts for Aerobic Oxidation* pp. 1-14. Springer.
- Patterson, A. 1939. The Scherrer formula for X-ray particle size determination. *Physical review* **56**(10): 978.
- Pegram, M. D., G. E. Konecny, C. O'Callaghan, M. Beryt, R. Pietras & D. J. Slamon 2004. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. *Journal of the National Cancer Institute* **96**(10): 739-749.

- Perkins, C. L., S.-H. Lee, X. Li, S. E. Asher & T. J. Coutts 2005. Identification of nitrogen chemical states in N-doped ZnO via x-ray photoelectron spectroscopy. *Journal of applied physics* **97**(3): 034907.
- Pernicova, I. & M. Korbonits 2014. Metformin [mdash] mode of action and clinical implications for diabetes and cancer. *Nature Reviews Endocrinology* **10**(3): 143-156.
- Perry, M. C. 2008. The chemotherapy source book Ed.: Lippincott Williams & Wilkins.
- Perz, J. F., G. L. Armstrong, L. A. Farrington, Y. J. Hutin & B. P. Bell 2006. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. *Journal of hepatology* **45**(4): 529-538.
- Peters, W. A., P. Liu, R. J. Barrett, R. J. Stock, B. J. Monk, J. S. Berek, L. Souhami, P. Grigsby, W. Gordon & D. S. Alberts 2000. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. *Journal of Clinical Oncology* **18**(8): 1606-1613.
- Peto, R., J. Boreham, M. Clarke, C. Davies & V. Beral 2000. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. *Lancet* **355**(9217): 1822.
- Pfeifer, M. A., G. J. Williams, I. A. Vartanyants, R. Harder & I. K. Robinson 2006. Three-dimensional mapping of a deformation field inside a nanocrystal. *Nature* **442**(7098): 63-66.
- Pieters, R., D. Huismans, A. Leyva & A. Veerman 1988. Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukemia. *Cancer letters* **41**(3): 323-332.
- Pinto, A. L. & S. J. Lippard 1985. Binding of the antitumor drug cis-diamminedichloroplatinum (II)(cisplatin) to DNA. *Biochimica et Biophysica Acta (BBA)-Reviews on Cancer* **780**(3): 167-180.
- Pissuwan, D., S. M. Valenzuela & M. B. Cortie 2006. Therapeutic possibilities of plasmonically heated gold nanoparticles. *TRENDS in Biotechnology* **24**(2): 62-67.
- Poizot, P., S. Laruelle, S. Grangeon, L. Dupont & J. Tarascon 2000. Nano-sized transition-metal oxides as negative-electrode materials for lithium-ion batteries. *Nature* **407**(6803): 496-499.
- Polzonetti, G., V. Caravetta, G. Iucci, A. Ferri, G. Paolucci, A. Goldoni, P. Parent, C. Laffon & M. Russo 2004. Electronic structure of platinum complex/Zn-porphyrinato assembled macrosystems, related precursors and model molecules, as probed by X-ray absorption spectroscopy (NEXAFS): theory and experiment. *Chemical physics* **296**(1): 87-100.

- Pop, C., J. Timmer, S. Sperandio & G. S. Salvesen 2006. The apoptosome activates caspase-9 by dimerization. *Molecular cell* **22**(2): 269-275.
- Portenoy, R. K. & P. Lesage 1999. Management of cancer pain. *The Lancet* **353**(9165): 1695-1700.
- Prabhakar, U., H. Maeda, R. K. Jain, E. M. Sevick-Muraca, W. Zamboni, O. C. Farokhzad, S. T. Barry, A. Gabizon, P. Grodzinski & D. C. Blakey 2013. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. *Cancer research* **73**(8): 2412-2417.
- Prime, R. B., H. E. Bair, S. Vyazovkin, P. K. Gallagher & A. Riga 2009. Thermogravimetric analysis (TGA). *Thermal Analysis of Polymers: Fundamentals and Applications*: 241-317.
- Purushotham, A. D., S. Upponi, M. B. Klevesath, L. Bobrow, K. Millar, J. P. Myles & S. W. Duffy 2005. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. *Journal of Clinical Oncology* **23**(19): 4312-4321.
- Pyrzyńska, K. & M. Bystrzejewski 2010. Comparative study of heavy metal ions sorption onto activated carbon, carbon nanotubes, and carbon-encapsulated magnetic nanoparticles. *Colloids and Surfaces A: Physicochemical and Engineering Aspects* **362**(1): 102-109.
- Raaschou-Nielsen, O., Z. J. Andersen, R. Beelen, E. Samoli, M. Stafoggia, G. Weinmayr, B. Hoffmann, P. Fischer, M. J. Nieuwenhuijsen & B. Brunekreef 2013. Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE). *The lancet oncology* **14**(9): 813-822.
- Rafique, S., M. Idrees, A. Nasim, H. Akbar & A. Athar 2010. Transition metal complexes as potential therapeutic agents. *Biotechnology and Molecular Biology Reviews* **5**(2): 38-45.
- Rajaram, V., S. Knezevich, K. E. Bove, A. Perry & J. D. Pfeifer 2007. DNA sequence of the translocation breakpoints in undifferentiated embryonal sarcoma arising in mesenchymal hamartoma of the liver harboring the t(11; 19)(q11; q13. 4) translocation. *Genes, Chromosomes and Cancer* **46**(5): 508-513.
- Ravdin, P. M., K. A. Cronin, N. Howlader, C. D. Berg, R. T. Chlebowski, E. J. Feuer, B. K. Edwards & D. A. Berry 2007. The decrease in breast-cancer incidence in 2003 in the United States. *New England Journal of Medicine* **356**(16): 1670-1674.
- Ray, J. C., R. K. Pati & P. Pramanik 2000. Chemical synthesis and structural characterization of nanocrystalline powders of pure zirconia and yttria stabilized zirconia (YSZ). *Journal of the European Ceramic Society* **20**(9): 1289-1295.

- Reddy, B. M. & M. K. Patil 2009. Organic syntheses and transformations catalyzed by sulfated zirconia. *Chemical reviews* **109**(6): 2185-2208.
- Reyes, J. D., B. Carr, I. Dvorchik, S. Kocoshis, R. Jaffe, D. Gerber, G. V. Mazariagos, J. Bueno & R. Selby 2000. Liver transplantation and chemotherapy for hepatoblastoma and hepatocellular cancer in childhood and adolescence. *The Journal of pediatrics* **136**(6): 795-804.
- Rezaie, A., R. D. Parker & M. Abdollahi 2007. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? *Digestive diseases and sciences* **52**(9): 2015-2021.
- Rieger, M. A., A. Parlesak, B. L. Pool-Zobel, G. Rechkemmer & C. Bode 1999. A diet high in fat and meat but low in dietary fibre increases the genotoxic potential offaecal water'. *Carcinogenesis* **20**(12): 2311-2316.
- Roos, W. P. & B. Kaina 2006. DNA damage-induced cell death by apoptosis. *Trends in molecular medicine* **12**(9): 440-450.
- Ross, R. & A. Fabian 2005. A comprehensive range of X-ray ionized-reflection models. *Monthly Notices of the Royal Astronomical Society* **358**(1): 211-216.
- Salvesen, G. S. & V. M. Dixit 1997. Caspases: intracellular signaling by proteolysis. *Cell* **91**(4): 443-446.
- Samantaray, S., G. Hota & B. Mishra 2011. Physicochemical characterization and catalytic applications of MoO<sub>3</sub>-ZrO<sub>2</sub> composite oxides towards one pot synthesis of amidoalkyl naphthols. *Catalysis Communications* **13**(12): 1255-1259.
- Samantaray, S., P. Kar, G. Hota & B. G. Mishra 2013. Sulfate grafted iron stabilized zirconia nanoparticles as efficient heterogenous catalysts for solvent-free synthesis of xanthenediones under microwave irradiation. *Industrial & Engineering Chemistry Research* **52**(17): 5862-5870.
- Samowitz, W. S., H. Albertsen, C. Sweeney, J. Herrick, B. J. Caan, K. E. Anderson, R. K. Wolff & M. L. Slattery 2006. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. *Journal of the National Cancer Institute* **98**(23): 1731-1738.
- Santen, R. J. & R. Mansel 2005. Benign breast disorders. *New England Journal of Medicine* **353**(3): 275-285.
- Santen, R. J., J. Pinkerton, C. McCartney & G. R. Petroni 2014. Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. *Journal of Clinical Endocrinology and Metabolism* **86**(1): 16-23.
- Santos, J. S., J. A. Dias, S. C. Dias, F. A. Garcia, J. L. Macedo, F. S. Sousa & L. S. Almeida 2011. Mixed salts of cesium and ammonium derivatives of 12-

- tungstophosphoric acid: Synthesis and structural characterization. *Applied Catalysis A: General* **394**(1): 138-148.
- Satia, J. A., M. K. Campbell, J. A. Galanko, A. James, C. Carr & R. S. Sandler 2004. Longitudinal changes in lifestyle behaviors and health status in colon cancer survivors. *Cancer Epidemiology Biomarkers & Prevention* **13**(6): 1022-1031.
- Sauter, E. R., W. Zhu, X. Fan, R. Wassell, I. Chervoneva & G. C. Du Bois 2002. Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer. *British journal of cancer* **86**(9): 1440-1443.
- Schadendorf, D., A. Paschen & Y. Sun 2000. Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma. *Immunology letters* **74**(1): 67-74.
- Schefter, T., K. Winter, J. S. Kwon, K. Stuhr, K. Balaraj, B. P. Yaremko, W. Small, W. Sause, D. Gaffney & R. T. O. Group 2014. RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma. *International Journal of Radiation Oncology\* Biology\* Physics* **88**(1): 101-105.
- Scheithauer, M., E. Bosch, U. A. Schubert, H. Knözinger, T.-K. Cheung, F. C. Jentoft, B. C. Gates & B. Tesche 1998. Spectroscopic and microscopic characterization of iron-and/or manganese-promoted sulfated zirconia. *Journal of Catalysis* **177**(1): 137-146.
- Schrag, D., L. D. Cramer, P. B. Bach & C. B. Begg 2001. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. *Journal of the National Cancer Institute* **93**(11): 850-857.
- Schraml, P., J. Kononen, L. Bubendorf, H. Moch, H. Bissig, A. Nocito, M. J. Mihatsch, O.-P. Kallioniemi & G. Sauter 1999. Tissue microarrays for gene amplification surveys in many different tumor types. *Clinical Cancer Research* **5**(8): 1966-1975.
- Schroeder, A., D. A. Heller, M. M. Winslow, J. E. Dahlman, G. W. Pratt, R. Langer, T. Jacks & D. G. Anderson 2012. Treating metastatic cancer with nanotechnology. *Nature Reviews Cancer* **12**(1): 39-50.
- Schuppan, D. & N. H. Afdhal 2008. Liver cirrhosis. *The Lancet* **371**(9615): 838-851.
- Schwimmer, H., A. Metzer, Y. Pilosof, M. Szyf, Z. M. Machnes, F. Fares, O. Harel & A. Haim 2014. Light at night and melatonin have opposite effects on breast cancer tumors in mice assessed by growth rates and global DNA methylation. *Chronobiology international* **31**(1): 144-150.
- Scott, H. 1975. Phase relationships in the zirconia-yttria system. *Journal of Materials Science* **10**(9): 1527-1535.

- Seddon, B. & P. Workman 2014. The role of functional and molecular imaging in cancer drug discovery and development. *The British journal of radiology*.
- Shaib, Y. & H. B. El-Serag 2004. The epidemiology of cholangiocarcinoma. *Seminars in liver disease*. **24** pp. 115-125.
- Shao, X. R., X. Q. Wei, X. Song, L. Y. Hao, X. X. Cai, Z. R. Zhang, Q. Peng & Y. F. Lin 2015. Independent effect of polymeric nanoparticle zeta potential/surface charge, on their cytotoxicity and affinity to cells. *Cell Proliferation*.
- Shi, Y. 2002. Apoptosome: the cellular engine for the activation of caspase-9. *Structure* **10**(3): 285-288.
- Siegel, R., J. Ma, Z. Zou & A. Jemal 2014. Cancer statistics, 2014. *CA: a cancer journal for clinicians* **64**(1): 9-29.
- Siegel, R., D. Naishadham & A. Jemal 2012. Cancer statistics, 2012. *CA: a cancer journal for clinicians* **62**(1): 10-29.
- Siegel, R. M., D. A. Martin, L. Zheng, S. Y. Ng, J. Bertin, J. Cohen & M. J. Lenardo 1998. Death-effector filaments: novel cytoplasmic structures that recruit caspases and trigger apoptosis. *The Journal of cell biology* **141**(5): 1243-1253.
- Silva, G. A. 2008. Nanotechnology approaches to crossing the blood-brain barrier and drug delivery to the CNS. *BMC neuroscience* **9**(Suppl 3): S4.
- Sing, K. 2001. The use of nitrogen adsorption for the characterisation of porous materials. *Colloids and Surfaces A: Physicochemical and Engineering Aspects* **187**: 3-9.
- Sinha, R., G. J. Kim, S. Nie & D. M. Shin 2006. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. *Molecular cancer therapeutics* **5**(8): 1909-1917.
- Skeel, R. T. & S. N. Khleif. 2011. Handbook of cancer chemotherapy Ed.: Lippincott Williams & Wilkins.
- Slattery, M., S. Edwards, K. Curtin, K. Ma, R. Edwards, R. Holubkov & D. Schaffer 2003. Physical activity and colorectal cancer. *American journal of epidemiology* **158**(3): 214-224.
- Slattery, M. L., J. D. Potter, W. Samowitz, D. Schaffer & M. Leppert 1999. Methylenetetrahydrofolate reductase, diet, and risk of colon cancer. *Cancer Epidemiology Biomarkers & Prevention* **8**(6): 513-518.
- Slee, E. A., M. T. Harte, R. M. Kluck, B. B. Wolf, C. A. Casiano, D. D. Newmeyer, H.-G. Wang, J. C. Reed, D. W. Nicholson & E. S. Alnemri 1999. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2,-3,-6,-7,-8, and -10 in a caspase-9-dependent manner. *The Journal of cell biology* **144**(2): 281-292.

- Smardzewski, J. 2015. The History of Furniture Construction. Dlm. (pnyt.). Ed. *Furniture Design* pp. 1-45. Springer.
- Smith, A. M., S. Dave, S. Nie, L. True & X. Gao 2006. Multicolor quantum dots for molecular diagnostics of cancer.
- Smith, R. A., D. Saslow, K. A. Sawyer, W. Burke, M. E. Costanza, W. Evans, R. S. Foster, E. Hendrick, H. J. Eyre & S. Sener 2003. American Cancer Society guidelines for breast cancer screening: update 2003. *CA: a cancer journal for clinicians* **53**(3): 141-169.
- Smith, T. A. & E. J. Brand 2001. Pancreatic cancer presenting as bleeding gastric varices. *Journal of clinical gastroenterology* **32**(5): 444-447.
- Smith, T. L. 2006. Breast cancer: current and emerging trends in detection and treatment Ed.: The Rosen Publishing Group.
- Sobin, L., M. K. Gospodarowicz & C. Wittekind 2008. Breast tumours. *TNM Online*.
- Sobin, L. H. & I. D. Fleming 1997. TNM classification of malignant tumors, (1997). *Cancer* **80**(9): 1803-1804.
- Solé, V., E. Papillon, M. Cotte, P. Walter & J. Susini 2007. A multiplatform code for the analysis of energy-dispersive X-ray fluorescence spectra. *Spectrochimica Acta Part B: Atomic Spectroscopy* **62**(1): 63-68.
- Song, X. & A. Sayari 1996. Sulfated zirconia-based strong solid-acid catalysts: recent progress. *Catalysis Reviews* **38**(3): 329-412.
- Sørlie, T., R. Tibshirani, J. Parker, T. Hastie, J. Marron, A. Nobel, S. Deng, H. Johnsen, R. Pesich & S. Geisler 2003. Repeated observation of breast tumor subtypes in independent gene expression data sets. *Proceedings of the National Academy of Sciences* **100**(14): 8418-8423.
- Sprintz, M., C. Benedetti & M. Ferrari 2004. Applied nanotechnology for the management of breakthrough cancer pain. *Minerva anestesiologica* **71**(7-8): 419-423.
- Stewart, B. W., P. Kleihues & I. A. f. R. o. Cancer. 2003. World cancer report Ed. 57. IARC press Lyon.
- Sumalla, E. C., C. Ochoa & I. Blanco 2009. Posttraumatic growth in cancer: reality or illusion? *Clinical psychology review* **29**(1): 24-33.
- Susi, H. & D. M. Byler 1986. Resolution-enhanced Fourier transform infrared spectroscopy of enzymes. *Methods in enzymology*(130): 290-311.
- Suzuki, Y., Y. Nakabayashi, K. Nakata, J. C. Reed & R. Takahashi 2001. X-linked inhibitor of apoptosis protein (XIAP) inhibits caspase-3 and -7 in distinct modes. *Journal of Biological Chemistry* **276**(29): 27058-27063.

- Suzuki, Y., Y. Nakabayashi & R. Takahashi 2001. Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. *Proceedings of the National Academy of Sciences* **98**(15): 8662-8667.
- Tait, S. W. & D. R. Green 2010. Mitochondria and cell death: outer membrane permeabilization and beyond. *Nature reviews Molecular cell biology* **11**(9): 621-632.
- Takemura, K. 2001. Evaluation of the hydrostaticity of a helium-pressure medium with powder X-ray diffraction techniques. *Journal of applied physics* **89**(1): 662-668.
- Tamm, I., Y. Wang, E. Sausville, D. A. Scudiero, N. Vigna, T. Oltersdorf & J. C. Reed 1998. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. *Cancer research* **58**(23): 5315-5320.
- Tan, G.-R., S.-S. Feng & D. T. Leong 2014. The reduction of anti-cancer drug antagonism by the spatial protection of drugs with PLA-TPGS nanoparticles. *Biomaterials* **35**(9): 3044-3051.
- Taori, K., J. Rathod, A. Deshmukh, V. S. Sheorain, R. Jawale, R. Sanyal, M. Bhagat & S. Jumle 2014. Primary extragonadal retroperitoneal teratoma in an adult. *The British journal of radiology*.
- Taylor, R. C., S. P. Cullen & S. J. Martin 2008. Apoptosis: controlled demolition at the cellular level. *Nature reviews Molecular cell biology* **9**(3): 231-241.
- Temel, J. S., J. A. Greer, A. Muzikansky, E. R. Gallagher, S. Admane, V. A. Jackson, C. M. Dahlin, C. D. Blidnerman, J. Jacobsen & W. F. Pirl 2010. Early palliative care for patients with metastatic non-small-cell lung cancer. *New England Journal of Medicine* **363**(8): 733-742.
- Thibault-Starzyk, F., I. Stan, S. Abelló, A. Bonilla, K. Thomas, C. Fernandez, J.-P. Gilson & J. Pérez-Ramírez 2009. Quantification of enhanced acid site accessibility in hierarchical zeolites—The accessibility index. *Journal of Catalysis* **264**(1): 11-14.
- Thomson, I. 2007. Abdolkarim H. Chehregani, Seyed Javad Sabounchi and Vida Jodaian. *Pakistan Journal of Biological Sciences* **10**(4): 641-644.
- Thorek, D. L., A. K. Chen, J. Czupryna & A. Tsourkas 2006. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. *Annals of biomedical engineering* **34**(1): 23-38.
- Tice, J. A., R. Miike, K. Adduci, N. L. Petrakis, E. King & M. R. Wrensch 2005. Nipple aspirate fluid cytology and the Gail model for breast cancer risk assessment in a screening population. *Cancer Epidemiology Biomarkers & Prevention* **14**(2): 324-328.

- Tölg, G. & R. Klockenkämper 1993. The role of total-reflection X-ray fluorescence in atomic spectroscopy. *Spectrochimica Acta Part B: Atomic Spectroscopy* **48**(2): 111-127.
- Toth, L. 2014. Transition metal carbides and nitrides Ed.: Elsevier.
- Tranmer, J. E., D. Heyland, D. Dudgeon, D. Groll, M. Squires-Graham & K. Coulson 2003. Measuring the symptom experience of seriously ill cancer and noncancer hospitalized patients near the end of life with the memorial symptom assessment scale. *Journal of pain and symptom management* **25**(5): 420-429.
- Trondl, R., P. Heffeter, C. R. Kowol, M. A. Jakupec, W. Berger & B. K. Keppler 2014. NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application. *Chem. Sci.*
- Turner, M., V. B. Golovko, O. P. Vaughan, P. Abdulkin, A. Berenguer-Murcia, M. S. Tikhov, B. F. Johnson & R. M. Lambert 2008. Selective oxidation with dioxygen by gold nanoparticle catalysts derived from 55-atom clusters. *Nature* **454**(7207): 981-983.
- van Rijt, S. H. & P. J. Sadler 2009. Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs. *Drug discovery today* **14**(23): 1089-1097.
- Veronesi, U., G. Paganelli, G. Viale, A. Luini, S. Zurrada, V. Galimberti, M. Intra, P. Veronesi, C. Robertson & P. Maisonneuve 2003. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. *New England Journal of Medicine* **349**(6): 546-553.
- von Roon, A. C., G. Reese, J. Teare, V. Constantinides, A. W. Darzi & P. P. Tekkis 2007. The risk of cancer in patients with Crohn's disease. *Diseases of the colon & rectum* **50**(6): 839-855.
- Wang, A. Z., R. Langer & O. C. Farokhzad 2012. Nanoparticle delivery of cancer drugs. *Annual review of medicine* **63**: 185-198.
- Wang, X. 2001. The expanding role of mitochondria in apoptosis. *Genes & development* **15**(22): 2922-2933.
- Wang, Y., Z. Li, J. Wang, J. Li & Y. Lin 2011. Graphene and graphene oxide: biofunctionalization and applications in biotechnology. *Trends in biotechnology* **29**(5): 205-212.
- Wang, Z. 2000. Transmission electron microscopy of shape-controlled nanocrystals and their assemblies. *The Journal of Physical Chemistry B* **104**(6): 1153-1175.
- Weckhuysen, B. M., D. Wang, M. P. Rosynek & J. H. Lunsford 1998. Conversion of methane to benzene over transition metal ion ZSM-5 zeolites: II. Catalyst

characterization by X-ray photoelectron spectroscopy. *Journal of Catalysis* **175**(2): 347-351.

Williams, D. B. & C. B. Carter. 1996. The transmission electron microscope Ed.: Springer.

Wilson, E. O. 1989. Threats to biodiversity. *Scientific American* **261**(3): 108-116.

Wolfe, E. & T. Chang 1987. Orally ingested microencapsulated urease and an adsorbent, zirconium phosphate, to remove urea in kidney failure. *The International journal of artificial organs* **10**(4): 269-274.

Wong, J. S., C. M. Kaelin, S. L. Troyan, M. A. Gadd, R. Gelman, S. C. Lester, S. J. Schnitt, D. C. Sgroi, B. J. Silver & J. R. Harris 2006. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. *Journal of Clinical Oncology* **24**(7): 1031-1036.

Wu, N.-L., S.-Y. Wang & I. Rusakova 1999. Inhibition of crystallite growth in the sol-gel synthesis of nanocrystalline metal oxides. *Science* **285**(5432): 1375-1377.

Wu, Y., L. Qin, G. Zhang, L. Chen, X. Guo & M. Liu 2013. Porous Solid Superacid SO<sub>42-</sub>/Fe<sub>2-x</sub>Zr<sub>x</sub>O<sub>3</sub> Fenton Catalyst for Highly Effective Oxidation of X-3B under Visible Light. *Industrial & Engineering Chemistry Research* **52**(47): 16698-16708.

Xiang, Y., N. Ma, D. Wang, Y. Zhang, J. Zhou, G. Wu, R. Zhao, H. Huang, X. Wang & Y. Qiao 2014. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. *Oncogene* **33**(3): 378-386.

Xin, X. 2015. Research on Prehistoric Hats in Xinjiang (2000 BC-200 BC). *Asian Social Science* **11**(7): p333.

Xu, H., Q. Li, L. Wang, Y. He, J. Shi, B. Tang & C. Fan 2014. Nanoscale optical probes for cellular imaging. *Chemical Society Reviews* **43**(8): 2650-2661.

Yadav, G. D. & J. J. Nair 1999. Sulfated zirconia and its modified versions as promising catalysts for industrial processes. *Microporous and mesoporous materials* **33**(1): 1-48.

Yamamoto, T., T. Tanaka, S. Takenaka, S. Yoshida, T. Onari, Y. Takahashi, T. Kosaka, S. Hasegawa & M. Kudo 1999. Structural analysis of iron and manganese species in iron-and manganese-promoted sulfated zirconia. *The Journal of Physical Chemistry B* **103**(13): 2385-2393.

Yan, W., R. Wang, Z. Xu, J. Xu, L. Lin, Z. Shen & Y. Zhou 2006. A novel, practical and green synthesis of Ag nanoparticles catalyst and its application in three-component coupling of aldehyde, alkyne, and amine. *Journal of Molecular Catalysis A: Chemical* **255**(1): 81-85.

- Yancik, R., M. N. Wesley, L. A. Ries, R. J. Havlik, B. K. Edwards & J. W. Yates 2001. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. *Jama* **285**(7): 885-892.
- Yang, D., A. Velamakanni, G. Bozoklu, S. Park, M. Stoller, R. D. Piner, S. Stankovich, I. Jung, D. A. Field & C. A. Ventrice 2009. Chemical analysis of graphene oxide films after heat and chemical treatments by X-ray photoelectron and Micro-Raman spectroscopy. *Carbon* **47**(1): 145-152.
- Yang, L., A. Zhang & X. Zheng 2009. Shrimp shell catalyst for biodiesel production. *Energy & Fuels* **23**(8): 3859-3865.
- Yang, R., C. R. Reilly, F. J. Rescorla, P. R. Faught, N. T. Sanghvi, F. J. Fry, T. D. Franklin, L. Lumeng & J. L. Grosfeld 1991. High-intensity focused ultrasound in the treatment of experimental liver cancer. *Archives of surgery* **126**(8): 1002-1010.
- Yang, Z., L. M. Schumaker, M. J. Egorin, E. G. Zuhowski, Z. Guo & K. J. Cullen 2006. Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. *Clinical Cancer Research* **12**(19): 5817-5825.
- Yao, F., Q. Wu, Y. Lei, W. Guo & Y. Xu 2008. Thermal decomposition kinetics of natural fibers: activation energy with dynamic thermogravimetric analysis. *Polymer Degradation and Stability* **93**(1): 90-98.
- Yarnold, J., A. Ashton, J. Bliss, J. Homewood, C. Harper, J. Hanson, J. Haviland, S. Bentzen & R. Owen 2005. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. *Radiotherapy and Oncology* **75**(1): 9-17.
- Yoneda, Y. & T. Horiuchi 1971. Optical Flats for Use in X-Ray Spectrochemical Microanalysis. *Review of Scientific Instruments* **42**(7): 1069-1070.
- Yu, C. & J. Irudayaraj 2005. Spectroscopic characterization of microorganisms by Fourier transform infrared microspectroscopy. *Biopolymers* **77**(6): 368-377.
- Zhang, L., J. Yang, J. Zhu, Z. Liu, B. Li, T. Hu & B. Dong 2002. Properties and liquefaction activities of ferrous sulfate based catalyst impregnated on two Chinese bituminous coals. *Fuel* **81**(7): 951-958.
- Zhang, X., A. J. Du, P. Lee, D. D. Sun & J. O. Leckie 2008. Grafted multifunctional titanium dioxide nanotube membrane: separation and photodegradation of aquatic pollutant. *Applied Catalysis B: Environmental* **84**(1): 262-267.
- Zhao, D.-L., X.-X. Wang, X.-W. Zeng, Q.-S. Xia & J.-T. Tang 2009. Preparation and inductive heating property of Fe<sub>3</sub>O<sub>4</sub>-chitosan composite nanoparticles in an AC magnetic field for localized hyperthermia. *Journal of Alloys and Compounds* **477**(1): 739-743.

- Zhou, L., J. Xu, X. Li & F. Wang 2006. Metal oxide nanoparticles from inorganic sources via a simple and general method. *Materials chemistry and physics* **97**(1): 137-142.
- Zhu, A. X., O. Rosmorduc, T. J. Evans, P. J. Ross, A. Santoro, F. J. Carrilho, J. Bruix, S. Qin, P. J. Thuluvath & J. M. Llovet 2015. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. *Journal of Clinical Oncology* **33**(6): 559-566.
- Zou, H., R. Yang, J. Hao, J. Wang, C. Sun, S. W. Fesik, J. C. Wu, K. J. Tomaselli & R. C. Armstrong 2003. Regulation of the Apaf-1/caspase-9 apoptosome by caspase-3 and XIAP. *Journal of Biological Chemistry* **278**(10): 8091-8098.
- Zou, X.-X., G.-D. Li, Y.-N. Wang, J. Zhao, C. Yan, M.-Y. Guo, L. Li & J.-S. Chen 2011. Direct conversion of urea into graphitic carbon nitride over mesoporous TiO<sub>2</sub> spheres under mild condition. *Chemical Communications* **47**(3): 1066-1068.
- Züttel, A., P. Sudan, P. Mauron, T. Kiyobayashi, C. Emmenegger & L. Schlapbach 2002. Hydrogen storage in carbon nanostructures. *International Journal of Hydrogen Energy* **27**(2): 203-212.